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Introduction 1
1 INTRODUCTION
1.1 BIOLOGY AND PHYLOGENY OF CHLAMYDIAEBacteria of the family Chlamydiaceae are obligate intracellular pathogens that infectboth humans and animals causing ocular, respiratory and sexually transmitted diseases [1].They are spherical eubacteria that resemble morphologically Gram-negative bacteria withinner and outer membranes [2]. Chlamydiaceae exhibit a unique biphasic developmentalcycle which occurs within cytoplasmic vacuoles, known as inclusions, in the eukaryotichost cells [3].Prior to the availability of molecular and genetic analysis, only four chlamydialspecies could be identified to compose the family Chlamydiaceae (Figure 1b). In taxonomybased on 16s RNA sequence analysis and DNA-DNA hybridization (Figure 1a), the family
Chlamydiaceae, which includes all commonly known chlamydiae species, was classified asone of four families composing the order Chlamydiales [4, 5]. The Chlamydiaceae familyconsists of two distinguishable genera, Chlamydia and Chlamydophila [4, 6].
Figure 1: Phylogenetic tree of the order Chlamydiales [7].
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1.1.1 Chlamydial infectionsThree species of chlamydiae are known to cause infections in humans (Figure 1),
Chlamydia trachomatis, Chlamydophila pneumoniae and Chlamydophila psittaci.
C. trachomatis is the species responsible for about 90 million cases of sexuallytransmitted diseases worldwide. About one third of this number is contributed to thedeveloped world [8]. Sexually transmitted C. trachomatis infection causes a pelvicinflammatory disease in women that may develop into scarring of the fallopian tubescausing infertility [9]. Additionally, C. trachomatis can cause ocular infections that are themain cause of blindness in developing countries [10, 11].
C. pneumoniae can cause respiratory tract infections. It is responsible for about 10%of community-acquired pneumonia cases and 5% of bronchitis and sinusitis cases.Infections are most common in children and most adults show serologic evidence of pastinfections [12].
C. psittaci is responsible for respiratory tract infections in birds. Infection canspread from birds to humans causing a rare type of pneumonia called psittacosis [13].
1.1.2 Life cycle of chlamydiaeThe Chlamydiales exhibit a unique biphasic developmental cycle that distinguishesthem from other intracellular bacteria [14]. Two forms of chlamydiae differentiate intoeach other during the life cycle, the elementary body (EB) and the reticulate body (RB)[15]. EBs represent the small (ca. 0.3 µm), spherical, extra-cellular form of chlamydiae[16, 17]. EBs are metabolically inactive but able to attach to and invade susceptible hostcells spreading the infection. Although all attempts to detect peptidoglycan (PG) in EBswere unsuccessful [2], they are rigid and osmotically stable, which is a result of high degreeof inter and intramolecular disulfide cross-linking of cysteine-rich proteins of the outerenvelope including OmpA, OmcB, and OmcA [14, 18, 19].In contrast to EBs, RBs are larger (ca. 1 µm), intracellular, and non-infectiouschlamydiae [18]. RBs are metabolically active and can divide inside host cells by repeated
Introduction 3cycles of binary fission. RBs are osmotically instable and need to be protected within amembrane-bound-vacuole, known as inclusion, that provides an isotonic environment forchlamydiae [2].
Figure 2: Developmental cycle of C. trachomatis [8].EB = elementary bodies & RB = reticulate bodiesThe developmental cycle (Figure 2) starts by attachment of the EBs to thesusceptible host cells, which occurs in two stages. The first stage is reversible and takesplace through electrostatic interactions between EBs and heparan sulfate receptors on hostcells [20, 21]. The second stage is an irreversible binding that was demonstrated usingmutagenized cell lines [22]. EBs entry into host cells is achieved via receptor-mediated-phagocytosis forming a membrane-bound-vacuole, termed inclusion [23]. Chlamydialinclusions do not fuse with endosomes and lysosomes, helping bacteria to bypass hostimmune system [14]. EBs within inclusions differentiate into the metabolically-active form,RBs, which divide by repeated cycles of binary fission. Finally, RBs differentiate back intoinfectious EBs, followed by lysis of host cells and release of EBs that infect adjacent cells
Introduction 4[18]. The chlamydial developmental cycle takes from 30 to 72 hours to complete accordingto the species [24].
1.1.3 Chlamydial anomalyBeing an obligate intracellular pathogen, chlamydiae have a very reduced genomesize, roughly 1.1 Mb, compared to free living bacteria like Escherichia coli (E. coli) (~ 4.6Mb) [25]. This feature reflects the evolutionary adaptation to host cell environment, whichsupports genome shrinkage. The genome of such organisms is thought to code onlyindispensable genes for their parasitic life [26]. Thus, chlamydiae do not need to keep cellwalls to maintain osmotic stability in their isotonic intracellular environment, and all trialsto detect PG failed to prove its presence [27].Like all other cell wall-less bacteria, chlamydiae were not expected to be susceptibleto antibiotics that target PG synthesis. Surprisingly, penicillin, and other antibiotics thattarget cell wall biosynthesis can interrupt the chlamydial developmental cycle [28-30]. Inpresence of penicillin, RBs can undergo 2 cycles of binary fission maximally. Prolongedexposure to penicillin leads to formation of aberrant enlarged RBs and the developmentalcycle enters a persistent, reversible, non-infectious state (Figure 3) [24]. Moreover, genesencoding a nearly complete pathway for the biosynthesis of cell-wall precursor lipid IIcould be found in chlamydial genome [25, 27]. This paradoxical phenomenon is known aschlamydial anomaly [27, 29].
Figure 3: Interference contrast microscope images of inclusions after 24 hours of
infection with C. trachomatis in absence (A) and presence (B) of penicillin [24].The white arrow highlights the different morphology.
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1.2 BACTERIAL CELLWALL BIOSYNTHESISThe cell wall in bacteria is the element responsible for maintaining cell shape andcell integrity by providing mechanical strength and resisting osmotic challenges [31]. Inboth Gram-positive and Gram-negative bacteria, the sacculus surrounding the cytoplasmicmembrane consists of cross-linked PG which is responsible for withstanding the highintracellular pressure [32, 33]. The PG synthesis is tightly connected to cell growth and celldivision processes in bacteria [31].PG biosynthesis is one of the main targets for antibiotic treatments as treating cellswith β-lactam antibiotics or any substance that inhibit cell wall biosynthesis leads to celllysis.
1.2.1 Chemical structure of peptidoglycanPeptidoglycan, the main component of the cell wall sacculus, consists of linearglycan strands cross-linked with short peptides [34]. The glycan strands are built up ofalternating units of N-acetylglucosamine (GlcNAC) and N-acetylmuramic acid (MurNAc)linked together by β-1,4-glycosidic bonds [33-36]. A stem peptide is attached to MurNAc byadding to its D-lactoyl group. This peptide consists mostly of L-Alanine-D-Glutamic acid-
meso-diaminopimelic acid (or L-lysine)-D-alanyl-D-alanine [33, 36] (Figure 4). In themature PG, the terminal D-alanine is removed during the process of cross-linking, whichtakes place between the carboxyl group of the D-alanine at position 4 and the amino groupof the diamino-acid at position 3 of an adjacent glycan strand [36]. This cross link may bedirect or via a short peptide bridge [31].
Figure 4: Chemical composition of the cell wall building block lipid II [37].
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1.2.2 Peptidoglycan biosynthesisThe biosynthesis of PG occurs in three stages (Figure 5): the first one takes place inthe cytoplasm, the second at the cytoplasmic membrane and the last stage occurs at theouter side of the cytoplasmic membrane [34, 38].Biosynthesis starts by the transfer of enolpyruvate from phosphoenolpyruvate(PEP) to UDP-GlcNAc with the help of UDP-GlcNAc-enoylpyruvate transferase (MurA)followed by reduction of enolpyruvate moiety into D-lactate with help of the reductaseenzyme (MurB) yielding UDP-MurNAc [39, 40]. To the D-lactoyl group of UDP-MurNAc,stepwise addition of amino acids takes place to form the stem peptide through Mur ligases(MurC, MurD, MurE and MurF). During this process the amino acids L-alanine (MurC), D-glutamic acid (MurD), dibasic amino acid (MurE) and dipeptide D-alanyl-D-alanine (D-ala-D-ala) are added sequentially yielding UDP-MurNAc-pentapeptide [31, 41]. The dibasicamino acid in the third position is either L-lysine (most Gram-positive bacteria) or meso-diaminopimelic acid (m-DAP) (most Gram-negative bacteria) [31, 36, 41]. The activity ofthe Mur ligases requires ATP hydrolysis and a divalent cation such as Mg2+ or Mn2+ [41].The dipeptide D-ala-D-ala is synthesized by the activity of the D-ala-D-ala ligase enzymeDdl and then ligated to the stem peptide by the activity of MurF enzyme [42, 43].The second stage of cell wall biosynthesis starts by the transfer of UDP-MurNac-pentapeptide moiety to the membrane lipid carrier undecaprenyl phosphate (C55-P orbactoprenol-P) yielding C55-PP-MurNAc-pentapeptide (lipid I) [44]. This reversiblereaction is catalyzed by UDP-MurNac-pentapeptide transferase (MraY), an integralmembrane protein, which transfers the reaction from the cytoplasm to cell membrane [45,46]. By the activity of a membrane associated protein, UDP-GlcNAc transferase (MurG),UDP-GlcNAc molecule is transferred to the hydroxyl group at position 4 of the muramoylmoiety of lipid I yielding the disaccharide building block C55-PP-GlcNAc-MurNAc-pentapeptide (Lipid II) [47, 48]. At the end of this stage, lipid II is translocated across thecell membrane by the activity of the lipid II flippase (FtsW) [49, 50].
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Figure 5: Schematic presentation of cell wall biosynthesis in E. coli.(I) First stage of cell wall biosynthesis in the cytoplasm starting from UDP-Glc-NAc resulting inUDP-Mur-NAc-pentapeptide. (II) Second stage of cell wall biosynthesis at the cytoplasmicmembrane leading to the synthesis of lipid I and lipid II. (III) Last stage of cell wall biosynthesis,incorporation of lipid II in cell wall and its recycling. (Scheme of Dr. Tanja Schneider)The last stage of cell wall biosynthesis involves the polymerization andincorporation of the newly synthesized lipid II molecules into the growing PG. Thesereactions are catalyzed mainly by a group of enzymes called penicillin binding proteins(PBPs) which activate the transglycosylation and transpeptidation reactions to polymerizethe glycan chains and to cross-link the peptides respectively [31, 37, 51].At the end, the released lipid carrier C55-PP is reactivated by hydrolysis of thepyrophosphate group and the release of the active lipid carrier C55-P by the enzyme C55-pyrophosphate phosphatase [52-54].
1.3 BACTERIAL CYTOSKELETON PROTEINSComparable to eukaryotes, bacteria use cytoskeletal proteins, such as actin andtubulin homologs, to control many cellular activities and processes, including cellmorphogenesis, cell division, DNA partitioning, and cell motility [55]. The bacterial
Introduction 8cytoskeleton consists of filamentous structures that are composed of polymers of singleprotein molecules. These proteins are capable of self-assembling into polymeric filaments
in vitro in the presence of conditions that favor their polymerization [56]. Four types ofcytoskeletal proteins are well established in rod shaped bacteria like E. coli, Bacillus subtilisand Caulobacter crescentus. Three of these four types have homology to eukaryotic actin,tubulin and intermediate filament proteins. The fourth type, MinD protein, has no clearhomologs in eukaryotic cells [57].
1.3.1 The bacterial actin homolog MreBMreB, the actin-related cytoskeletal protein, plays an important role in regulation ofcell shape, cell polarity and chromosome segregation in bacteria [56, 58]. It is widelydistributed in bacteria with complex morphology (rods, vibrios and spirilla) but absent inmost bacteria with spherical morphology [57, 59]. Some bacteria like E. coli possess asingle MreB protein, while others (mostly Gram-positive) contain multiple MreB copies like
B. subtilis which has MreB, Mbl and MreBH [56, 60]. mreB-knockout mutants and MreBdepleted cells lose their typical shape and generate enlarged cells with majormorphological defects [61-63].MreB and actin are members of a superfamily of proteins, which includes Hsp70,cell division protein FtsA and sugar kinases. While all members of this superfamily havevery little amino acid sequence identity, they share the characteristic actin core and itsthree dimensional fold which consists of α and β domains folding around a central core, thenucleotide-binding pocket [58, 59]. Among all these proteins MreB and actin are the mostclosely related in overall size [64]. With the exception of MreB and actin, the activities ofthese protein superfamily members are totally divergent and have little to do withcytoskeleton, but they are capable of binding and hydrolyzing ATP at their equivalentATPase domain [64].MreB is considered to organize into helical filaments that coil around the rod shapedcells under the surface of the cytoplasmic membrane [56]. Nevertheless, results from arecent study using total internal reflection fluorescence microscopy indicate that MreBmight assemble into small patches in B. subtilis, E. coli and C. crescentus [65]. In vitro, MreB
Introduction 9proteins self-assemble into long polymeric filaments and the filaments interact to formbundles of solid-like structures with high elasticity that is thought to play a role insupporting cell shape. However, the highly dynamic nature of MreB and its continuousredistribution within cells suggest that rigidity of MreB polymers might not be essential forsupporting cell shape [56]. This idea was supported by the effect of A22 (S-(3,4-dichlorobenzyl)isothiourea), a substance that inhibits MreB polymerization [66, 67], inrod-like shaped C. crescentus. Treating C. crescentus with A22 causes shape alteration verylate in comparison to the disappearance of helical MreB structures [68]. It is likely thatMreB maintains the shape of rod-shaped bacteria by orienting the PG biosynthetic enzymesto tether incorporation of cell wall precursors into the side-wall during the longitudinalgrowth [56, 59]. MreB filaments are thought to recruit and functionally organize enzymesinvolved in cell wall biosynthesis including soluble (MurB, MurC, MurE and MurF) andmembrane (MraY and MurG) proteins [65]. The MreB organized machinery is connected tothe PBP2 catalyzed lipid II precursor polymerization reactions on the outside through amembrane-spanning complex consisting of MreC, MreD and RodA [32, 61, 65, 69] (Figure6A). MreB filaments are flexible and highly dynamic structures that move continuouslythrough the cell [59]. During cell divison, MreB filaments are rearranged into twocircumferential rings that flank the cytokinetic FtsZ ring (section 1.3.2). The cytoskeletalMreB rings are suggested to be involved in the early cell division process, preseptalelongation and segregation of the cytoskeleton and show interactions with MreC, MreD andRodA as well [32, 70] (Figure 6B).
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Figure 6: Schematic presentation of the organization of cytoskeleton-associated cell
wall synthesizing proteins in E. coli.(A) MreB and membrane associated proteins position PBPs during cell wall elongation.(B) Circumferential ring MreB flanks FtsZ ring which recruits enzymes for peptidoglycan synthesisto the septum during preseptal elongation [32].
1.3.2 The bacterial tubulin homolog (FtsZ)Despite enormous progress in the last decade towards the identification of proteinsinvolved in cell division and their mode of assembly, the biochemical functions of severaldivision proteins are still poorly understood [71, 72]. Currently, the following stages ofbacterial cell division are recognized: the tubulin homolog FtsZ assembles into an annularstructure (Z-ring) at the site of division and initiates cell division by attracting a set ofproteins to form a cytoplasmic apparatus linked to the membrane; then additionalelements build an extracellular connector; and finally, proteins (e.g. transpeptidase FtsI(PBP3) and flippase FtsW) involved in the incorporation of septal peptidoglycan assemble(Figure 7). The process ends with constriction of the septum [71, 73]. According to theresults from the localization of green fluorescent protein fusions or the immunostaining ofthe proteins in cell division mutants, the division proteins are recruited into the divisomemachinery in a sequential and almost linear pathway [74, 75].
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Figure 7: Schematic presentation of cell division machinery in E. coli [32].During cell division, FtsZ protein builds up the Z-ring, which recruits other proteins that composethe divisome machinery.The bacterial tubulin homolog FtsZ is an important cell division protein and almostubiquitously distributed in bacteria, archae and eukaryotic organelles [56]. Like tubulin,FtsZ binds and hydrolyze GTP and its polymerization is GTP dependant [76, 77].
1.4 CYTOSKELETON AND CELL DIVISION PROTEINS IN CHLAMYDIAEChlamydiae were expected to harbor the essential cytokinesis protein FtsZ and lackthe rod-shape maintaining protein MreB. Surprisingly, chlamydiae lack the highlyconserved FtsZ but harbor, despite their spherical shape, MreB [25].For cell division, a rudimentary set of divisome proteins lacking the almostubiquitous central organizer FtsZ, but including FtsW, FtsI, FtsH, FtsK and FtsY has beenfound to be encoded by chlamydial genomes [78].
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1.5 LIPID II BIOSYNTHESIS IN CHLAMYDIAEThe complete genome analysis of chlamydiae at the end of the 1990s [25] revealed anearly complete pathway for the synthesis of lipid II in chlamydiae [27, 79-81] (Figure 9).Moreover, the nucleotide oligomerization domains NodI and NodII can recognizeintracellular C. pneumoniae and subsequently mediate activation of the nuclear factor κβ(NF-κβ) playing a key role in regulating the immune response to infection [82, 83]. Nodreceptors are members of the human cytosolic innate immune pattern recognitionreceptors sensing bacterial cell wall fragments [84-86], NodI has been described torecognize lipid II containing m-DAP [85, 87] whereas NodII has been described torecognize MurNAc-dipeptide fragments of cell wall [88, 89].In all Gram-negative bacteria, the division cell wall (dcw) cluster is highlyconserved. On the other hand, this gene cluster in the intracellular chlamydiae shows someunique differences such as the fusion of ddl to murC and the localization of the murE geneoutside the dcw cluster (Figure 8).[2]
Figure 8: Comparison of the dcw cluster of E. coli and C. trachomatis [27].ORF= open reading frame encoding product of unknown function.So far, few studies have been conducted to investigate whether chlamydial genes ofthe PG biosynthesis pathway encode functional enzymes. These studies proved thefunctionality of MurA, Murc-Ddl, MurE and MurF, enzymes involved in the cytoplasmicsynthesis steps of the PG precursor UDP-MurNAc-pentapeptide [90-94].Additionally, the functionality of MraY and MurG, enzymes responsible respectivelyfor lipid I and lipid II biosynthesis at the cytoplasmic membrane, has been demonstrated in
vitro [95]. Concerning the last stage of cell wall biosynthesis in chlamydiae at the outersurface of the cytoplasmic membrane, the chlamydial genomes lack glycosyltransferases
Introduction 13that catalyze the formation of linear glycan chains of PG [2]. However, polymerization of PGprecursor could be achieved through the transpeptidase activity of the monofunctionalPBP2 and PBP3 encoded in chlamydial genomes [78]. Moreover, Chlamydiae lackendopeptidases which allow remodeling of the wall PG [2]. Cleavage of lipid II by theactivity of the chlamydial amidase AmiA could be demonstrated in vitro [diploma thesis ofAnna Klöckner].The recycling of lipid carrier C55-PP at the end of the biosynthetic pathway is stillunclear. Pyrophosphorylases that can activate the lipid carrier by dephosphorylation arenot present in chlamydial genomes.The exact composition of the chlamydial lipid II pentapeptide side chain is still amatter of debate. It was shown that chlamydiae are able to synthesize m-DAP via anaminotransferase pathway through the activity of CT390 and DapF proteins [96]. Thechlamydial genomes do not encode the racemases Alr and MurI, enzymes that catalyze theinterconversion of L- and D- optical isomers of alanine and glutamic acid respectively [2].This finding suggests that D-amino acids may not be part of chlamydial lipid II. However,the functionalities of Ddl domain of the MurC-Ddl fusion protein as D-ala-D-ala ligase [94]and MurF as D-alanyl-D-alanine adding enzyme [92] suggest that D-alanine should be apart of the chlamydial lipid II peptide side-chain. Indeed, no clear source for D-alaninecould be proven until now and the hypothesis of D-alanine uptake from the host cell ishighly questioned [2]. However, Patin et al. [92] postulated a peptide side chain inchlamydiae composed of L-alanine/L-serine/glycine-γ-D-glutamic acid-m-DAP-D-alanyl-D-alanine.
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Figure 9: Hypothetical model for the lipid II biosynthesis pathway in chlamydiae
(modified from [95]).Genes not found in the genome are highlighted in red crosses. Question marks and dashed arrowsindicate steps that need to be elucidated.
1.6 SERINEHYDROXYMETHYL TRANSFERASES (SHMTS)Serine hydroxymethyl transferases (SHMTs) are enzymes that catalyze thereversible interconversion of serine and glycine with tetrahydrofolate serving as onecarbon acceptor [97, 98]. SHMTs are widely distributed in mammalians, plants andprokaryotes [99]. The enzymes catalyze several reactions characteristic of pyridoxal-Penzymes. Noteworthy, rabbit liver cytosolic and E. coli SHMTs have been demonstrated tocatalyze the racemization reaction of D- and L-alanine in vitro [98]. In a recent study, a D-alanine E. coli auxotrophic strain was constructed by deletion of alr and dadX, coding foralanine racemases. Proteome analysis of this auxotrophic strain and its phenotypicprototrophic revertant strain revealed that the SHMTs GlyA was one of the significantly
Introduction 15upregulated proteins in the phenotypic revertant together with other proteins involved inmethionine synthesis [100].Interestingly, the very-reduced chlamydial genome harbors a glyA gene.Additionally, phylogentic analysis of the conserved inserts in chlamydial glyA providesevidence that the gene has undergone lateral exchange with other free living actinobacteria[101] indicating that this gene is of great necessity for such intracellular pathogens.
1.7 COORDINATION OF CELL-WALL BIOSYNTHESIS AND CELL
DIVISION IN PROKARYOTESIn rod shaped bacteria such as E. coli or B. subtilis, cell wall biosynthesis is acontinuous process during cell elongation and cell division. On the other hand, round-shaped bacteria show cell wall biosynthesis only at the division septum [37]. At the septum,cell wall biosynthesis and cell division processes are both driven by partially overlappingmachineries. The activity of both machineries needs to be tightly coordinated to maintaincell integrity. A recent finding suggests that peptidoglycan biosynthesis at the cell wall isdriven by a multi-enzyme complex that is directly connected to the cell division machinery.For example, FtsI (PBP3), transpeptidase incorporating lipid II at the septum (section1.2.2) is a crucial member of the divisome machinery.
1.8 ROLE OF THE LIPID II BIOSYNTHESIS PATHWAY IN CELL
DIVISIONFor intracellular bacteria, such as chlamydiae, the highly-energy consumingbiosynthesis of PG appears to be superfluous. Nevertheless, several findings discussed insection 1.5 clearly confirm that the biosynthesis pathway of cell wall building block lipid IIis conserved in the wall-less chlamydiae suggesting another essential role of the precursorbesides cell wall biosynthesis in bacteria.Recently, it was hypothesized that conservation of lipid II biosynthesis inintracellular bacteria reflects an intimate molecular linkage of cell division and cell wallbiosynthesis and thus a vital role of the completed cell wall building block in cell division
Introduction 16[95] (Figure 10). Apparently, an entire cycle of lipid II biosynthesis and processing,including translocation of the precursor to the outside and recycling of the membranecarrier C55-P is required for coordinated function of the cell division machinery [95].
Figure 10: Proposed model for a link between lipid II biosynthesis pathway and cell
division [95]Lipid II is synthesized via a fully conserved pathway and then processed by a rudimentary cell wallbiosynthesis-cell division machinery (Ftsw, FtsH, FtsK, FtsY). This machinery may contain MraY,MurG, PBPs and division proteins. Lipid II translocation to the outer side of the cell membrane andlipid carrier C55-P recycling are required for coordinated function of the divisome machinery [95].This hypothesis is strongly supported by the results of a study on the division ofchloroplasts in mosses. Chloroplasts with disrupted MurE were unable to divide and grewin the form of macrochloroplasts due to inability to synthesize a functional lipid II [102]. Aconnection between lipid II biosynthesis and cell division in chlamydiae is also confirmedby aspects of the chlamydial anomaly. Penicillin does not show its normal bactericidaleffect in chlamydiae, but stops the developmental cycle at the stage of RB division leadingto formation of atypically enlarged non-dividing RBs within expanded inclusions [24].
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1.9 PENICILLIN BINDING PROTEINSPenicillin binding proteins (PBPs) are membrane bound enzymes, which areessential for the final steps of PG biosynthesis [37, 103]. Four different physiologicalfunctions are possibly assigned to PBPs (Figure 11). (i) Transglycosylation, in which PBPscatalyze the polymerization of disaccharide units forming glycan strands, (ii)transpeptidation, in which PBPs catalyze the cross-linking of the peptide stem, (iii) DD-carboxypeptidation, in which PBPs hydrolyze the terminal D-alanine of the peptide stemlimiting the extent of PG cross-linking, or finally (iv) endopeptidation, which is the reverseactivity of transpeptidation where PBPs hydrolyze the peptide bond cross-linking theglycan strands [103]. PBPs belong to a larger family of proteins known as acyl serinetransferases, which includes both PBPs and β-lactamases [104].
Figure 11: Schematic presentation of PBPs activities.According to their molecular mass, PBPs can be classified into high molecular mass(HMM) PBPs and low molecular mass (LMM) PBPs [37, 103]. HMM-PBPs are composed oftwo modules anchored to the outer surface of the cytoplasmic membrane [37] and areresponsible for peptidoglycan polymerization into growing cell wall [105, 106]. The HMM-PBPs are further classified according to the structure and activity of their N-terminaldomain into class A and class B HMM-PBPs. While the C-terminal domain of all HMM-PBPsshows transpeptidase activity, the N-terminal domain of class A provides transglycosylaseactivity [103]. In class B, the N-terminal domain is believed to be involved in maintaining
Introduction 18cell morphology by providing a recognition site for interaction with other proteins duringthe cell cycles [33, 107, 108]. Monofunctional transglycosylases (MGTs), with similarity tothe N-terminal domain of class A HMM-PBPs, are also found in some bacteria [109-111].LMM-PBPs are monofunctional DD-carboxypeptidases or endopeptidases [104, 112].Bacteria have a variable number of PBPs which are historically numbered accordingto their migration on SDS-PAGE [103]. E. coli possesses twelve PBPs, three (PBP1a, PBP1band PBP1c) are class A HMM-PBPs, two (PBP2 and PBP3) are class B HMM-PBPs, and sevenLMM-PBPs exhibit DD-carboxypeptidase or endopeptidase activities [37, 103]. Althoughthe biochemical activities of all these PBPs are known, their exact role within the cell is stillnot completely determined. E. coli can survive even with inactivation of eight of thesetwelve PBPs [113]. PBP1a and PBP1b are the major transpeptidases-transglycosylases in
E. coli. Deletion of one of them is not lethal but inactivation of both results in autolysis[114-116]. PBP2 is essential for cell elongation and its loss results in spherically-shapedcells instead of rods [117]. By contrast, the second monofunctional transpeptidase PBP3 isinvolved in cell division and its absence causes cell filamentation [118, 119]. Only PBP2 andPBP3 in combination with either PBP1a or PBP1b are necessary to maintain the phenotypeof wild-type E. coli [113].
1.10 PENICILLIN BINDING PROTEINS IN CHLAMYDIAEThe sensitivity of chlamydiae to penicillin and other β-lactams has been related tothe presence of PBPs [29, 120], and three PBPs were detected in lysated C. trachomatisusing direct labeling with radioactive penicillin [120]. In accordance, three open readingframes encoding proteins with homology to PBPs have been found in chlamydial genomes[78, 112]. Amino acid sequence analysis of the three chlamydial PBPs indicates that two ofthem are class B HMM-PBPs equivalent to PBP2 and PBP3 from E. coli with themonofunctional transpeptidases and the third PBP can be classified under LMM-PBPs withgreatest similarity to the carboxypeptidase PBP6a from E. coli [2, 27, 121].
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2 AIM OFTHEPROJECT
2.1 FUNCTIONAL ANALYSIS OF CHLAMYDIALMREBBased on the hypothesis that lipid II biosynthesis may have to be maintained forfunctional cell division, MreB could be involved in coordinating cell division via tetheringthe biosynthesis of lipid II to the chlamydial septum. In this project, it was investigatedwhether chlamydial MreB (i) polymerizes in vitro, (ii) hydrolyzes nucleotides and (iii)interacts with proteins involved in lipid II biosynthesis, such as MurF, MraY and MurG.
2.2 STUDIES ON THE STRUCTURE OF CHLAMYDIAL LIPID IIPBPs bind their substrate via a D-alanyl-D-alanine (D-ala-D-ala) residue at the C-terminus of the pentapeptide side chain of lipid II. To investigate the presence of such atarget in chlamydiae, I will check the capability of chlamydiae to synthesize D-alanine.
Chlamydiaceae lack the alanine racemase enzyme responsible for the synthesis of D-alaninein all other eubacteria but encode the serine hydroxymethyltransferase (SHMT) GlyA thathas been shown to catalyze racemization of D- and L- alanine. In order to test if GlyAactivity can provide a way to synthesize D-alanine in Chlamydiaceae, the racemase activityof chlamydial GlyA was investigated in vitro.
2.3 FUNCTIONAL ANALYSIS OF PBPS FROM CHLAMYDIAEChlamydiae harbor genes encoding three PBPs which resemble PBP2, 3, and 6a from
E. coli. PBP2 and PBP3 from E. coli are mono-functional transpeptidases, which cross-linkglycan chains via peptide bridges in free-living bacteria. PBP6a from E. coli shows DD-carboxypeptidase activity responsible for the removal of terminal D-alanine of the peptideside chain blocking transpeptidation. Chlamydial PBPs might be essential for theprocessing of lipid II at the septum catalyzing the release of the membrane carrierbactoprenol. To analyze the functionality of PBPs in chlamydiae, the three proteins werecloned, over-produced and purified, and tests were established to detect their activities
in vitro.
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3 MATERIALS ANDMETHODS
3.1 MATERIALS
3.1.1 Reagents and chemicalsReagents and chemicals utilized in this work are listed in Table 1 and were ofanalytical grade or better.
Table 1: Chemicals and materials
Company Chemical nameAgilent Technologies/Stratagene(Waldbronn, Germany) QuickChange Lightning Site-DirectedMutagenesis KitBaker (Griesheim, Germany) Chloroform, methanol, water (HPLC-grade)Biorad (München, Germany) Bradford protein assayFermentas/Thermo Sientific (St. Leon-Rot,Germany) GeneRuler 1 kb DNA ladder, PageBlue,Pierce protein gel (4-20% SDS, 12 und 17Well), Pierce 4x LDS sample buffer, Topvision agarose, Tris-Hepes-SDS-runningbuffer, Zeba Desalt Spin columnsFulka (Steinheim, Germany) Imidazole, Bovine serum albumin(BSA),Triton X-100Hannah Instruments (Kehl am Rhein,Germany) Calibration solutions pH 4,1/ pH7,1Larodan Fine Chemicals (Malmö, Sweden) Undecaprenylphosphat (C55-P)Macherey-Nagel (Düren, Germany) Ni2+-NTA-AgaroseMerck (Darmstadt, Germany) Agar-Agar, ammonium carbonate (NH4CO3),ammonium sulfate (NH4)2SO4, 1-butanol,disodium hydrogen phosphate·dihydrat(Na2HPO4 2 H2O), acetic acid glucosemonohydrate, yeast extract, 2-[4-(2-Hydroxyethyl)-1-piperazinyl]-ethansulfonicacid (Hepes), potassium chloride (KCl),potassium hydroxide, silica gel plates 0,25nm, magnesium sulfate (MgSO4), Sodiumchloride (NaCl), sodium dihydrogenphosphate dihydrat (NaH2PO4 2 H2O).EGTA,MreB perturbing substance A22, perchloric
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Company Chemical nameacidMP Biomedicals (Illkirch, GmbH) Glycerol, tryptoneNew England Biolabs (Ipswich, USA) Desoxynucleotide (dNTPs), physion DNApolymerase, protein marker 7702S,restriction enzymesOperon (Ebersberg, Germany) Oligonucleotide (primers)Pharmacia Biotech (Düsseldorf, Germany) Dithiothreitol (DTT)Qiagen (Hilden, Germany) QIAprep Spin Miniprep kit, polypropylencolumns (1 ml), Minelute PCR purificationKitRoche (Basel, CH) T4-DNA-Ligase, 10x ligation bufferRoth (Kalsruhe, Germany) Ethidium bromide-solution, sodium dodecylsulfate (SDS)-pelletsSigma-Aldrich (Steinheim, Germany) Adenosine triphosphate (ATP), ammoniumhydroxide, ampicillin sodium, D-alanyl-D-alanine, D-glutamic acid, dimethyl sulfoxide(DMSO), desoxyribonuclease (DNase),ferrous (II)-sulfate heptahydrate(FeSO4·7H2O), isopropyl-β-D-thiogalactopyranosid (IPTG), kanamycin, L-lysine, lysozyme, magnesiumchloridehexahydrate (MgCl2·6H2O), meso-diaminopimelic acid (m-DAP), N-dodecyl-β-maltoside (DDM), nicotinamide-adenine-dinucleotide (NADPH), sodiumlauroylsarcosin, o-nitrophenyl-β-D-galactopyranosid (ONPG), perchloric acid,ribonuclease A (RNase A), thiaminehydrochlorid, Tris base, Tris hydrochlorid,uridine diphosphate N-acetylglucosamine(UDP-GlcNAc), zinc sulfate (ZnSO4), α-chymotrypsin, β-mercaptoethanol, PGsacculi from B. Subtilis
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3.1.2 Utensils and laboratory equipmentsAll equipments, labware and consumables used in this work, together with theirrespective manufacturers and suppliers, are listed in Table 2.
Table 2: Utensils and laboratory equipments
Manufacturers EquipmentsAbimed GmbH (Langenfeld, Germany) Automatic pipette Gilson Pipetman P2, P20,P100, P200, P1000, P5000AEG (Berlin, Germany) MicrowaveAgfa-Gevaert N.V.(Mortsel, Belgium) Agfa scanner SnapScanTM e40Barnstead International (Dubuque, Iowa,USA) Deionizer, Easy Pure LF®Beckman Coulter Inc. (Fullerton, USA) Centrifuge: J2-21Bibby Sterlin Ltd. (Stone Staffordshire, GB) Rotary evaporator RE 100BioRad Laboratories (München, Germany) Thermocycler iCycler, Molecular ImagerGelDoc XR+, Image Lab Software Version2.0.1Branson (Danbury, USA) Ultrasonic bath Bransonic 1510 E-MTBraun Biotech International (Melsungen,Germany) Centrifuge Sigma 2K 15, shaking water bathCERTOMAT® H, 1 ml syringes, OMNIFIX®Dr. Hielscher Ultrasonics GmbH (Teltow,Germany) Ultrasonic homogenizer UP50HEppendorf (Hamburg, D) MiniSpin® microfugeGesellschaft für Labortechnik (GFL,Burgwedel, D) Shaking water bath 1083Glaswerk Wertheim (Wertheim, Germany) ExicatorGrant Instruments (Cambridge, UK) Heating block QBH2Hannah Instruments (Kehl am Rhein,Germany) HI 221 Microprocessor pH-MeterHarry Gestigkeit GmbH (Düsseldorf,Germany) Precision hot plateHeraeus Holding (Hanau, Germany) 37°C incubator, Rotator incubator, Biofuge28 RS, rotator incubatorHeraeus Sepatech GmbH (Osterode,Germany) Centrifuge, Biofuge 28RS, rotors 3751,
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Manufacturers EquipmentsImplen (München, Germany) NanophotometerTM 7122v1.6.1Invitrogen (Carlsbad, USA) Novex Mini Cell (SDS-Gel-chamber)Julabo Labortechnik GmbH (Selbach,Germany) Mini water bath Julabo MWBMartin Christ (Osterode, Germany) Freeze-dryerPALL GmbH (Dreieich, Germany) Sterile Acrodisc® syringe filters, 0.2 µmPaul Hartmann AG (Heidenheim, Germany) Disposable gloves, Peha/Soft®Pfeiffer (Asslar, Germany) Vacuum pump Duo5Renner (Darmstadt, Germany) Gel chamberSartorius (Göttingen, Germany) Analytical balance A 200 S, microbalanceMP3 and universal balanceScientific Industries Inc. (New York, USA) Vortexer Vortex Genie2Tecan (Männedorf, CH) Sunrise, NanoQuant (micro titer platereader), Magellan6 (Software)Thermo Fisher Scientific Inc. (Waltham,USA) Autoclave, Varioklav®Thermo Scientific (Langenselbold,Germany) Sorvall Evolution RC Superspeed centrifugeVWR (Darmstadt, Germany) Power supply 300 VVWR (Langenfeld, Germany) Microtiter platesWilhelm Werner GmbH (Leverkusen,Germany) Demineralizer, AQUADEM®
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3.1.3 Bacterial strains and plasmidsBacterial strains and plasmids used or constructed during this study are listed inTable 3 and Table 4
Table 3: Bacterial strains
Bacterial strain Chromosomal
genotype
Application Reference
Chlamydophila
pneumoniae GDI Clinical strain forisolation of genomicDNA AG Hegemann(University ofDüsseldorf)
Escherichia coliW3110 (DSM3871) Wild/type strain forpreparation ofpeptidoglycan DSMZ (Braunschweig)
Escherichia coliDH5α fhuA2 _(argF-lacZ)U169, phoA,glnV44, Φ80_(lacZ)M15, gyrA96,recA1, relA1, endA1,thi-1, hsdR17
Cloning strain Invitrogen (Carlsbad,USA)
Escherichia coliBL21 (DE3) F-ompT gal dcmlonhsdSB(rB-mB-)λ(DE3 [lacI lacUV5-T7gene 1 ind1 sam7 nin5])
Expression strain forcytoplasmic proteinexpression Novagen/Merck(Darmstadt, GermanyEurolab)
Escherichia coliTop 10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15ΔlacX74 nupG recA1araD139 Δ(ara-leu)7697 galE15 galK16rpsL(StrR) endA1 λ-
Cloning strain Invitrogen (Carlsbad,USA)
Escherichia coliJM109 endA1 glnV44 thi-1relA1 gyrA96 recA1mcrB+ Δ(lac-proAB)e14- [F' traD36 proAB+lacIq lacZΔM15]hsdR17(rK-mK+)
Cloning strain New England Biolabs(Ipswich, USA)
Escherichia coliLemo21 (DE3) fhuA2 [lon] ompT gal (λDE3) [dcm]∆hsdS/pLemo(CamR)λ DE3 = λ sBamHIo∆EcoRI-Bint::(lacI::PlacUV5::T7gene1) i21∆nin5
Expression strain fortoxic andtransmembraneproteins
New England Biolabs(Ipswich, USA)
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Bacterial strain Chromosomal
genotype
Application ReferencepLemo = pACYC184-PrhaBAD-lysY
Escherichia coliBH101 F-, cya-99, araD139,galE15, galK16, rpsL1(Strr), hsdR2, mcrA1,mcrB1
Reporter strain for theBACTH system (β-galactosidase assay) Euromedex(Souffelweyersheim,France)
Escherichia coliDHM1 F-, cya-854, recA1,endA1, gyrA96 (Nalr), thi1, hsdR17,spoT1, rfbD1,glnV44(AS)
Reporter strain for theBACTH system (β-galactosidase assay) Euromedex(Souffelweyersheim,France)
Escherichia coliXL-10 Gold TetrΔ (mcrA)183Δ(mcrCB-hsdSMR-mrr)173 endA1supE44 thi-1 recA1gyrA96 relA1 lac the[F´ proAB lacIqZΔM15Tn10 (Tetr) AmyCamr]
Cloning strain for themutagenesis kit Agilen Technologies(Waldbronn,Germany)
Mirococcus luteusDSM1790 For membranepreparation DSMZ (Braunschweig,Germany)
Staphylococcus
simulans 22ATCC 12559 Indicator strain for theproduction of cell wallprecursor Kloos and Schleifer(1975) [122]
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Table 4: Plasmids
Plasmid Plasmid size
[bp]
Resistance
marker†
Description ReferencepET-21b(+) 5442 AmpR Expression vector,T7promoter, C-terminalHis-tag Novagen (MerckEurolab)pET-52b(+) 5227 AmpR Expression vector,T7promoter, C-terminalHis-tag, N-terminal
Strep-tag
Novagen (MerckEurolab)
pASK-IBA3 3247 AmpR Expression vector,
tetA promoter, C-terminal Strep-tag II IBA-BioTAGnologypASK-IBA5 3260 AmpR Expression vector,
tetA promoter, N-terminal Strep-tag II IBA-BioTAGnologypKT25 3442 KanR Expression vector,
lac promoter,derivative of plasmidpSU40, encodes T25fragment upstreamMCSǂ
Euromedex,(Souffelweyersheim,France)
pKNT25 3469 KanR Expression vector,
lac promoter,derivative of plasmidpSU40, encodes T25fragmentdownstream MCSǂ
Euromedex,(Souffelweyersheim,France)
pUT18C 3017 AmpR Expression vector,
lac promoter,derivative of plasmidpUC19, encodes T18fragment upstreamMCSǂ
Euromedex(Souffelweyersheim,France)
pUT18 3023 AmpR Expression vector,
lac promoter,derivative of plasmidpUC19, encodes T18fragmentdownstream MCSǂ
Euromedex(Souffelweyersheim,France)
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Plasmid Plasmid size
[bp]
Resistance
marker†
Description ReferencepKT25 zip 3556 KanR Derivative of pKT25,leucine zipper isfused to the T25fragment
Euromedex(Souffelweyersheim,France)pUT18C zip 3119 AmpR Derivative ofpUT18C, Leucinezipper is fused to theT18 fragment
Euromedex(Souffelweyersheim,France)pKJE7 7200 CmR Chaperone plasmid Takara Bio Inc. (Kyoto,Japan)
Recombinant
plasmidspET21b-pbp2
PBP2 from C.
pneumoniae GDI 8715 AmpR Expression vector,T7-promoter, PBP2with C-terminal 6xHis-Tag
This work
pET21b-PBP3
PBP3 from C.
pneumoniae GDI 7404 AmpR Expression vector,T7 promoter, PBP3with C-terminal 6xHis-Tag
This work
pET21b-dacF
dacF from C.
pneumoniae GDI 6753 AmpR Expression vector,T7 promoter, PBP6awith C-terminal 6xHis-Tag
This work
pET21b-mreB
mreB from C.
pneumoniae GDI 6543 AmpR Expression vector,T7 promoter, MreBwith C-terminal 6xHis-Tag
C. Otten
pASK-IBA3-pbp2
PBP2 from C.
pneumoniae GDI 6520 AmpR Expression vector,tetA promoter, PBP2with C-terminalStrep-Tag II
This work
pASK-IBA3-PBP3
PBP3 from C.
pneumoniae GDI 5209 AmpR Expression vector,tetA promoter, PBP3with C-terminalStrep-Tag II
This work
pASK-IBA3-dacF
dacF from C. 4558 AmpR Expression vector,tetA promoter,PBP6a with C- This work
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Plasmid Plasmid size
[bp]
Resistance
marker†
Description Reference
pneumoniae GDI terminal Strep-Tag IIpASK-IBA3-mreB
mreB from C.
pneumoniae GDI 4348 AmpR Expression vector,tetA promoter, MreBwith C-terminalStrep-Tag II
C. Otten
pASK-IBA5-pbp2
PBP2 from C.
pneumoniae GDI 6533 AmpR Expression vector,tetA promoter, PBP2with N-terminalStrep-Tag II
This work
pASK-IBA5-PBP3
PBP3 from C.
pneumoniae GDI 5222 AmpR Expression vector,tetA promoter, PBP3with N-terminalStrep-Tag II
This work
pASK-IBA5-dacF
dacF from C.
pneumoniae GDI 4571 AmpR Expression vector,tetA promoter,PBP6a with N-terminal Strep-Tag II
This work
pET-21b-glyA
glyA from C.
pneumoniae GDI 7002 AmpR Expression vector,T7 promoter, GlyAwith C-terminal 6xHis-Tag
This work
pET-52b-glyA
glyA from C.
pneumoniae GDI 6987 AmpR Expression vector,T7 promoter, GlyAwith C-terminal 6xHis-Tag and N-terminal Strep-tag
This work
Recombinant
plasmids for the
BACTH systempKNT25-PBP3
PBP3 from C.
pneumoniae GDI 5431 KanR Expression vector,lac promoter, PBP3fused with T25-fragment at N-terminus
This work
pUT18-PBP3
PBP3 from C.
pneumoniae GDI 5404 AmpR Expression vector,lac promoter, PBP3fused with T18-fragment at N-terminus
This work
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Plasmid Plasmid size
[bp]
Resistance
marker†
Description ReferencepKNT25-dacF
dacF from C.
pneumoniae GDI 4780 KanR Expression vector,lac promoter, PBP6afused with T25-fragment at N-terminus
This work
pUT18-dacF
dacF from C.
pneumoniae GDI 4753 AmpR Expression vector,lac promoter, PBP6afused with T18-fragment at N-terminus
This work
pKNT25-mreB
mreB from C.
pneumoniae GDI 4570 KanR Expression vector,lac promoter, MreBfused with T25-fragment at N-terminus
Dr. B. Henrichfreise
pUT18-mreB
mreB from C.
pneumoniae GDI 4543 AmpR Expression vector,lac promoter, MreBfused with T18-fragment at N-terminus
Dr. B. Henrichfreise
pKNT25-mraY
mraY from C.
pneumoniae GDI 4519 KanR Expression vector,lac promoter, MraYfused with T25-fragment at N-terminus
Dr. B. Henrichfreise
pUT18-mraY
mraY from C.
pneumoniae GDI 4492 AmpR Expression vector,lac promoter, MraYfused with T18-fragment at N-terminus
Dr. B. Henrichfreise
pKNT25-murG
murG from C.
pneumoniae GDI 4543 KanR Expression vector,lac promoter, MurGfused with T25-fragment at N-terminus
Dr. B. Henrichfreise
pUT18-murG
murG from C.
pneumoniae GDI 4516 AmpR Expression vector,lac promoter, MurGfused with T18-fragment at N-terminus
Dr. B. Henrichfreise
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Plasmid Plasmid size
[bp]
Resistance
marker†
Description ReferencepKNT25-amiA
amiA from C.
pneumoniae GDI 4264 KanR Expression vector,lac promoter, AmiAfused with T25-fragment at N-terminus
K. Schulz
pUT18-amiA
amiA from C.
pneumoniae GDI 4237 AmpR Expression vector,lac promoter, AmiAfused with T18-fragment at N-terminus
K. Schulz
†	AmpR	=	Ampicillin	resistance,	KanR=	Kanamycin	resistance,	CmR	=	Chloramphenicol	resistance.ǂ MCS = multiple cloning site
3.1.4 Culture MediaTable 5 includes the growth media used for the cultivation of the bacterial strainsdeployed in this work. Unless otherwise indicated, the culture media were dissolved indeionized distilled water sterilized by autoclaving for 20 min. at 121°C. Heat-sensitivesubstances, sugars and antibiotics were dissolved separately in appropriate solvents andadded to the autoclaved media after they cooled down to 50°C
Table 5: Culture media
Culture medium CompositionLuria-Bertani (LB)-agar 10 g/l NaCl, 10 g/l trypton, 5 g/l yeastextract, 15 g/l agar-agar, pH 7.5Luria-Bertani (LB)-medium 10 g/l NaCl, 10 g/l trypton, 5 g/l yeastextract, pH 7.5NZY+ broth 10 g/l NZ amine (casein hydrolysate), 5 g/lyeast extract, 5 g/l NaCl, 12,5 ml MgCl2 (1M), 12.5 ml MgSO4 (1 M), 20 ml Glucose(20% (w/v)), pH 7.5SOC-medium 20 g/l trypton, 5 g/l yeast extract, 10 mMNaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mMMgSO4, 20 mM Glucose, pH 7.5MacConkey (Difco Laboratories)/maltosemedium 40 g/l MacConkey base, 10g/l maltose, 0.5mM IPTG
Materials and Methods 31
3.1.5 AntibioticsAntibiotics used in this study for the preparation of selective media are listed inTable 6.
Table 6: Antibiotics
Antibiotic Stock solution
(mg/ml)
Solvent Supplier/SourceAmpicillin 100 Distilled water Sigma-AldrichKanamycin 50 Distilled water Sigma-AldrichChloramphenicol 100 Ethanol (100 %) Sigma-Aldrich hAnhydrotetracycline 2 Ethanol (100 %) IBA-BioTAGnology
3.2 MICROBIOLOGICALMETHODS
3.2.1 Cultivation bacterial strainsAll bacterial strains used in this study were stored as glycerol cultures (40 % v/v) at-70°C. Streaking on LB agar plates was used to cultivate E. coli strains from glycerolcultures. Inoculated plates were incubated at 37°C overnight and then kept at 4°C. Selectivepressure of the appropriate antibiotics (Table 6) was used to propagate E. coli strains thatharbor resistance plasmids (Table 4).Unless otherwise indicated, cultivation in liquid media was performed aerobically at37°C with shaking at 150 rpm in a shaking water bath (CEROMAT® H). To prepare a mainculture for protein over-expression, 2% (v/v) inoculum from an overnight preculture wasused to prepare the main culture.
3.2.2 Preparation of glycerol culturesFor long-term storage of bacterial strains, separate colonies of the correspondingstrains from fresh LB agar plates were mixed with pre-autoclaved LB medium and 85%glycerol (1:1) in screw-capped freezing vials. Alternatively, 0.6 ml logarithmic-phase E. coli
Materials and Methods 32cultures in LB medium were pipetted into pre-autoclaved screw-capped freezing vialscontaining 0.4 ml 100% glycerol and vortexed vigorously. Glycerol cultures were storeddirectly after preparation at -70°C.
3.2.3 SterilizationThe sterilization of glassware was carried out at 200°C for 4 hours in hot air oven.Culture media, buffers, pipette tips and centrifugation bottles were autoclaved at 121°C for20 minutes. Stock solutions containing heat-sensitive substances like antibiotics and sugarswere sterilized by filtration through 0.2 µm membrane filters.
3.2.4 Measurement of optical density of liquid culturesThe cell density of bacterial suspensions was determined by measuring the opticaldensity (OD) of appropriately diluted samples using a spectrophotometer at a wavelengthof 600 nm [OD600], against the respective suspending medium as a blank.
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3.3 MOLECULARBIOLOGICALMETHODS
3.3.1 Isolation of genomic DNAGenomic DNA of C. pneumoniae GDI was kindly supplied by Prof. Dr. Hegemann(University of Düsseldorf, Germany).
3.3.2 Isolation of plasmid DNA from E. coli culturesPlasmid DNA was isolated from E. coli cultures using the Qiaprep® Miniprep kit(Qiagen GmbH), according to the manufacturer’s instructions. The Qiaprep miniprepprocedure uses a modified alkaline lysis method of Birnboim and Doly [123]. In thismethod, the bacterial cells, after harvesting and resuspension, are lysed in NaOH/SDSbuffer. The anionic detergent SDS denatures phospholipids and protein contents of the cellmembrane leading to cell lysis and release of cell content. The alkaline pH does not helponly to break down the cell wall but also to denature both genomic and plasmid DNA insidethe cells. Acidified potassium acetate buffer is then used to neutralize the lysate and toadjust it to high salt content. Under these conditions, small circular plasmid DNA renatureswhile SDS denatured proteins, chromosomal DNA, and cellular debris are precipitated andcleared by centrifugation. DNA in the cleared lysate can bind selectively to silica membranein the Qiaprep columns. After washing steps, DNA was eluted in 50 µl distilled water(50°C). The plasmid DNA was used directly for restriction reactions, transformation,sequencing or stored at -20°C.
3.3.3 Photometric determination of DNA concentrationDNA concentration was measured through photometric analysis byNanophotometer (Implen). Because of its nitrogenous bases content, DNA absorbs in theUltraviolet (UV) range, at a wavelength of 260 nm. A reading of 1.0 at 260 nm correspondsto 50 µg/ml of pure double stranded DNA and the more concentrated the DNA solution, themore UV light it absorbs [124].
Materials and Methods 34DNA purity can be estimated by calculating the ratio A260/A280. A ratio of 1.8represents a high-purity DNA. Ratios lower than 1.8 indicate contamination with proteinswhile ratios higher than 1.8 indicate contamination with RNA.
3.3.4 Agarose gel electrophoresis of DNAAgarose gel electrophoresis is a method to separate nucleic acid fragments bylength. In this method, DNA fragments are separated by applying an electric field to movenegatively charged molecules from the cathode to the anode through an agarose matrix[124]. Several factors affect the rate of migration of DNA through agarose gels, including:
 the size of the DNA. Smaller DNA molecules migrate faster than larger onesbecause they can move easily through gel pores,
 the concentration of agarose. The higher the agarose concentration, theslower the rate of DNA migration,
 the conformation of the DNA. Superhelical circular, nicked circular and linearDNA conformations migrate in agarose gel in different rates,
 applied voltage and the type of agarose.DNA samples analyzed by gel electrophoresis should be mixed with a loading buffer,which helps DNA to sink in the sample well and visualizes the migration duringelectrophoresis through two tracking dyes. Ethidium bromide is a fluorescent dye thatintercalate non-specifically between DNA bases causing DNA to fluoresce under UVlight (254 nm).In this study, 1% agarose (Fermentas GmbH) was cooked in 1X tris acetate buffer(TAE) using microwave (AEG) until agarose melted completely. After cooling down to60°C, ethidium bromide was added to a final concentration of 0.5 µg/ml. The gel waspoured into a casting tray containing a suitable comb and allowed to solidify at roomtemperature. Before loading on the gel, samples were mixed with loading buffer.Electrophoresis was done in an electrophoresis chamber filled with 1X TAE buffer.With the help of DNA ladder (Table 7), the size of the analyzed DNA fragments wasdetermined.
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Table 7: DNA ladder for agarose gel electrophoresis
DNA ladder DNA-Fragments (bp) SourceGeneRulerTM 1kb DNALadder 250, 500, 750, 1.000, 1.500,2.000, 2.500, 3.000, 3.500, 4.000,5.000, 6.000, 8.000, 10.000 Fermentas GmbH
3.3.5 Polymerase chain reaction (PCR)The polymerase chain reaction is a technique developed by Kary Mullis [125] toamplify a specific DNA segment in vitro. In addition to the target DNA, a PCR reactionrequires several other ingredients. A pair of primers that hybridize the target DNA at areasflanking the segment to be amplified, free deoxyribonucleotides (dNTPs), and heat stableDNA polymerase which uses the dNTPs to fill the gap between both primers. The PCRreaction relies on repeated (30-40 cycles) thermal cycling. Each cycle consists of threethermal steps:
 DNA denaturation, samples are heated up more than 95°C to separate the DNAdouble strands,
 annealing step, in which the reaction is cooled down to 50-70°C to allow the primerpair to hybridize their DNA target,
 DNA extension, in which the reaction temperature is raised up to 72°C, at whichDNA polymerase synthesizes a new DNA strand complementary to the DNA templatestrand by adding dNTPs in 5' to 3' direction.The product of each cycle can be used as a template for the next cycles allowingalmost exponential amplification. The thermal cycles are usually preceded by a single stepof initial denaturation and followed by a step of final extension.In this study, Phusion High-Fidelity PCR kit (NEB) was used to prepare the PCRreactions according to the manufacturer recommendations. The Phusion DNA polymerasegenerates long templates with high accuracy and speed. The PCR reactions were achievedusing iCycler (BioRad).
Materials and Methods 36DNA primers used to amplify DNA segments during this study were synthesized byEurofins MWG Operon and listed with their specific restriction enzymes, annealingtemperatures and extension time in Table 8.The PCR reaction components and pipetting scheme are shown in Table 9. The exactthermal profile used for each pair of primers is shown in Table 10. During the design ofprimers to amplify DNA for cloning purpose, different recognition site was introduced ineach of the primer pair to direct the DNA fragment during cloning.
3.3.5.1 Colony PCRColony PCR was used to detect positive clones during cloning process. Positiveclones are bacterial clones that received a vector in which an insert was introduced duringligation step. Colony PCR uses the same reaction as normal PCR with minor modifications.A small amount of the bacterial colony is used as template instead of the genomic DNA inthe PCR reaction (Table 9) and the initial denaturation step is extended to 5 min instead of30 seconds (Table 10) to help the release of the bacterial DNA before the amplificationcycles.
Table 8: Oligonucleotide primers
Gene
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Oligonucleotide Sequence (5'-3')§
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PBP2(3273)pASK-IBA3
PBP2-Cp-IBA3F ATGGTAGGTCTCAAATGAAACGACCGAAAAAATTTCCTATTTAT BsaI† 67.5 90PBP2-Cp-IBA3R ATGGTAGGTCTCAGCGCTTCCCCTTAAAAAAGATTCTCTTTGTT BsaIPBP2(3273) PBP2-Cp-IBA5F ATGGTAGGTCTCAGCGCCATGAAACGACCGAAAAAATTTCCTAT BsaI 67.5 90
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pASK-IBA5 PBP2-Cp-IBA5R ATGGTAGGTCTCATATCATCCCCTTAAAAAAGATTCTCTTTGTT BsaI
PBP2(3273)pET-21b
PBP2-Cp-pET-F CATAATATCTATCATATGAAACGACCG NdeI 59 90PBP2-Cp-pET-R AAAGCGGCCGCTCCCCTTAAAAAAG NotIPBP3(1962)pASK-IBA3
PBP3-Cp-F TATCATATGAGCTACCGTAAACG NdeI 57 60PBP3-Cp-IBA3R GTTGAATTCATGAGCTACCGTAAACGTTC EcoRIPBP3(1962)pASK-IBA5
PBP3-Cp-F TATCATATGAGCTACCGTAAACG NdeI 57 60PBP3-Cp-IB5R GTTGAATTCGATGAGCTACCGTAAACGTT EcoRI
PBP3(1962)pET-21b
PBP3-Cp-F TATCATATGAGCTACCGTAAACG NdeI 57 60PBP3-Cp-R AGACTCGAGCCTCGTTCCCCCTTG XhoI
dacF(1311) PBP6a-IBA3-F ATGGTAGGTCTCAAATGAAAAGACCTTTTTTTACCTATCTATGC BsaI 65 40
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pASK-IBA3 PBP6a-IBA3-R ATGGTAGGTCTCAGCGCTGATTTTAGAATAGTGTTTTAAATTTTTATA BsaI
dacF(1962)pASK-IBA5
PBP6a-IBA5-F ATGGTAGGTCTCAGCGCCATGAAAAGACCTTTTTTTACCTATCTA BsaI 65 40PBP6a-IBA5-R ATGGTAGGTCTCATATCAGATTTTAGAATAGTGTTTTAAATTTTTATA BsaI
dacF(1962)pET-21b
PBP6a-pET-F CAAAAGTCCGGCTAGCAAAAGACCTTTT NheI 55 40PBP6a-pET-R GAAACTCGAGGATTTTAGAATAG XhoI
murF(1344)pASK-IBA5
MurF-Cp-F AAACCGCGGGGCGAGCTATGTTGCTTG SacII 55 40MurF-Cp-R CTAAGCCATGGAAAACAAGCTAATAAG NcoI
murF(1344)pET-21b
MurF-Cp-F GCAAAATGCTAGCCGAGCTATGTTGC NheI 65 40MurF-Cp-R CCTAGCGGCCGCAAAACAAGCTAATAAG NotI
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glyA(1560)pET-21b
GlyA-pET21-F CGTCTTTAGAAGCATATGCTAAAAG NdeI 58 40GlyA-pET21-R GTCTCTGCGGCCGCAACTAAAGCTTC NotI
glyA(1560)pET-52b
GlyA-pET52-F CTTTAGAAGCCCGGGCTAAAAGTTTTTG SmaI† 61 60GlyA-pET52-R GTCTCTCCGAGCTCAACTAAAGCTTC SacI
PBP3(1962)BACTH
PBP3-BACTH-F GTCTTTTACTGCAGTAGCTACCGTAAACG PstI 65 60PBP3-BACTH-R ATAGAGGATCCTCCCTCGTTCCCCCTTG BamHI
dacF(1311)BACTH
PBP6A-BACTH-F CAAAAGTCCTCTAGAGAAAAGACCTTTT XbaI 57.5 40PBP6A-BACTH-R AAAAGAGGTACCAAGATTTTAGAATAG KpnI§ The underlined sequence shows the recognition site of the used restriction endonucleases.†	All	 restriction	endonucleases	used	cut	within	 their recognition site to produce sticky ends withthe exception of BsaI, which cuts outside its recognition site producing sticky ends and SmaI, whichcuts inside its recognition site producing blunt ends.
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Table 9: Pipetting scheme for PCR reactions
Component PCR Colony PCRH2O Add to 50 µl Add to 15 µl5x Phusion HF Buffer 10 µl 3 µl10 mM dNTPs 1 µl 0.3 µlForward primer (10 pmol/ µl) 2.25 µl 0.75 µlReverse primer (10 pmol./ µl) 2.25 µl 0.75 µlTemplate DNA 50 ng Small amount of the colonyPhusion DNA polymerase 1 unit 0.3 unit
Table 10: PCR thermal profile
PCR step Temperature (°C) Time RepetitionsInitial denaturation 98 30 sec 1PCRamplificationcycles Denaturation 98 10 sec 35 cyclesAnnealing Table 8 20 secExtension 72 Table 8Final extenion 72 10 min 1Cooling down 4 ∞ 1
3.3.5.2 Purification of DNA fragmentsDNA fragments from PCR reactions, agarose gel or enzymatic reactions werepurified using MinElute PCR purification kit (Qiagen) according to the manufacturerinstructions. During DNA purification, all enzymes, salts and oligomers smaller than 70 bpwere removed during the column loading and washing. DNA fragments with sizes between70 bp and 4 kb were eluted in 10-15 µl of distilled water.
3.3.6 Site directed mutagenesisCysteine 345 in chlamydial MreB was changed to alanine, producing C345A MreBmutant, using QuikChange® Lightning Site-Directed Mutagenesis kit (Agilent Technologies)according to manufacturer's instructions. The basic procedure (Figure 12) utilizes adouble-stranded DNA plasmid with insert of interest and two synthetic oligonucleotide
Materials and Methods 41primers containing the desired mutation. The primers, each complementary to oppositestrands of the vector, were extended with thermal cycling to produce a mutated plasmidcontaining staggered nicks. The product of the thermal cycling step was treated with DpnIto digest the parental DNA. The nicked vector DNA containing the desired mutations wasthen transformed into XL-Gold ultracompetent cells.The mutagenic primers used to produce C345A MreB mutant are shown in Table 11.
Figure 12: Schematic presentation of mutagensis kit principle
Table 11: Mutagenic primers used for C345AmreB synthesis
Oligonucleolide Sequence (5'-3')§mreB C345A sense CATCCTTTGCTGGCAGTTGCTTTAGGAACCGGGAAAGCmreB C345A antisense GCTTTCCCGGTTCCTAAAGCAACTGCCAGCAAAGGATG§ The underlined sequence represents the position of mutation
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3.3.7 Cloning
3.3.7.1 DNA restriction with restriction endonucleasesRestriction endonucleases are enzymes that recognize specific nucleotide sequencesknown as recognition sites and produce a double-stranded cut in the DNA by hydrolyzingthe DNA-phosphodiester bonds. In bacteria, it is considered as a defense mechanismagainst foreign DNA like invading viruses [126]. The recognition site in most cases ispalindormic and consists of 4-8 nucleotides. According to their properties, DNA restrictionendonucleases are classified into three main types. While type I and III cleave DNA outsidetheir recognition site, type II enzymes cleave DNA within or at short specific distance fromtheir recognition sites.All restriction enzymes used in this work are of type II (Table 8) and haverecognition site of 6 palindormic nucleotides except NotI (8 nucleotides). All cut DNAwithin the recognition site with the exception of BsaI (cuts outside the recognition site) toproduce sticky-ended DNA with the exception of SmaI (produce blunt-ended DNA). Allrestriction reactions were performed according to the manufacturer's instructions.
3.3.7.2 Dephosophorylation of the linearized vectorsDuring ligation step, the ligase enzyme catalyzes the formation of a phosphodiesterbond between 5' phosphate group and 3' hydroxyl group of two adjacent DNA strands.Thus, the removal of 5' phosphate from a linear plasmid can minimize self-ligation ofplasmid.In this work, antarcatic phosphatase (NEB) was used to dephosphorylate restrictedvectors following the manufacturer's instructions.
3.3.7.3 Purification of DNA after enzymatic reactionsAt the end of DNA restriction and dephophorylation reactions, DNA was purifiedusing MinElute Reaction Cleanup columns (Qiagen) according to the manufacturer'sinstructions. DNA fragments were purified from enzymes and salts as illustrated in 3.3.5.2.
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3.3.7.4 DNA ligationT4 DNA ligase is an enzyme that links DNA fragments together by forming aphosphodiester covalent bond between 5' phosphate and 3' hydroxyl groups of twoadjacent fragments [124]. The enzyme can catalyze the ligation of both complementarysticky-ended DNA fragments, produced by cutting both vector and insert using the samerestriction enzyme, and blunt-ended DNA.In this work, T4 DNA ligase (Roche) was used according to the manufacturer'sinstructions.
3.3.7.5 Concentrating DNA samplesDNA samples with low concentration were concentrated using SpeedVac (Savant) at35°C for 30-45 minutes under vacuum.
3.3.8 Expression vectorsSeveral expression vectors were used during this work (Table 4)
3.3.8.1 pASK-IBA3 and pASK-IBA5pASK-IBA vectros (IBA-BioTAGnology) are Strep-tag II expression vectors that carrythe promoter/operator region from the tetA resistance gene. These vectors provide tightrepression of the promoter by the constitutive expression of the tet repressor gene. Theover-production of the heterologous protein can be fully induced by addinganhydrotetracycline at a concentration that is not antibiotically effective (200 ng/ml). Thestrength of the tetA promoter is nearly 25% the activity of the T7 promoter.pASK-IBA3 and pASK-IBA5 (Figure 13) introduce a C-terminal and N-terminal Strep-tag II to the cloned protein respectively. The Strep-tag II is a short peptide (8 amino acids,WSHPQFEK), which binds with high selectivity to Strep-Tactin, an engineered streptavidin.Thus, the binding affinity to Strep-Tactin can be used for purification of recombinantproteins. Both vectors encode ampicillin resistance gene and use ampicillin as a selectionmarker.
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Figure 13: Vector map of pASK-IBA3 plus and pASK-IBA5 plus* expression vectors
(IBA-BioTAGnology)* The plus vectors are identical to the non-plus vectors but contain an improved translationinitiation site.
3.3.8.2 pET-21b and pET-52b expression vectorspET vectors (Novagen) are vectors in which target genes are cloned under control ofthe strong bacteriophage T7 promoter which is specific to T7 RNA polymerase provided bythe host E. coli strains. The expression in pET system is under the control of lac operatorand promoter. The addition of isopropyl-β-thiogalactopyranoside (IPTG) induces theexpression of the chromosomally encoded T7 polymerase, which replaces the repressorfrom the vector lac operon starting protein transcription and translation.pET-21b vector (Figure 14) introduces a hexa histidine-tag (His-tag) at the C-terminus of the recombinant protein which facilitates the protein purification using nickelnitroactic acid (Ni-NTA) resin or TALON metal affinity resin. On the other hand, pET-52bvector (Figure 14) encodes two fusion proteins; a C-terminal His-tag and an N-terminal
Strep-tag; allowing double protein purification using Ni-NTA resin and Strep-Tactinsepharose.
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Figure 14: Vector map of pET-21a* and pET-52b expression vectors (Navagen)* pET-21b is similar to pET-21a but one nucleotide less in size (5442 bp).
3.3.8.3 SequencingThe confirmation of the correctness of the cloned genes was achieved by sequencingthe plasmid-DNA at SeqLab (Göttingen). Primers used for sequencing are listed in Table 12.
Table 12: Primers for sequencing
Vector Primer name Sequence (5'-3')pASK-IBA3 and pASK-IBA5 5IBA3 GAGTTATTTTACCACTCCCTIBA2r CGCAGTAGCGGTAAACGpET-21b and pET-52b T7 TAATACGACTCACTATAGGGT7 term GCTAGTTATTGCTCAGCGGBACTH-pUT18 pUT18_F TTTATGCTTCCGGCTCGTATGTTpUT18_R CAAGTCGATGCGTTCGCGATBACTH-pKNT25 pKNT25_F CTTTACACTTTATGCTTCCGpKNT25_R CTTCGCCACGGCCTTGATGC
3.3.9 Transformation in competent bacteriaDuring this work, transformation of plasmid DNA into E. coli strains, during cloningor for protein over-expression, was achieved using chemo-competent E. coli cells.
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3.3.9.1 Preparation of chemo-competent E. coliLB medium (200 ml) was infected with 1% (v/v) overnight culture of E. coli strains.Culture was incubated in a shaking water bath (GFL) at 37°C and about 100 rpm until OD600of 0.4-0.5. The cells were harvested by centrifugation (Heraeus Biofuge 28RS, rotor: 3751,5300 rpm, 20 minute, 4°C). Cell pellet was resuspended in 80 ml ice-cold 0.1 M CaCl2solution. Cell suspension was incubated on ice for 20 minutes and then harvested bycentrifugation (see above). Pellet was resuspended in 2 ml 0.1 M CaCl2 solution in 15%glycerol and incubated for an hour on ice. Chemo-competent cells were divided as 60 µlaliquots in pre-cooled eppendorfs and stored directly at -70°C.
3.3.9.2 Transformation in CaCl2-competent E. coliAn aliquot of CaCl2-competent cells was thawed gently on ice. Plasmid DNA (10 ngor 5 µl ligation product) was added to the cells and incubated on ice for 30 minutesfollowed by heat shock in water bath (Julabo) at 42°C for 90 seconds. Cells were incubatedon ice for 2 minutes. SOC medium (1 ml) was added to the cells and the transformationtube was incubated in a shaking incubator (Braun) for an hour at 37°C and 140 rpm. At theend, appropriate volumes (2-250 µl) of the transformation reaction were plated on LB agarsupplemented with the proper concentration of the corresponding resistance markercarried by the transformed plasmids. LB agar plates were incubated at 37°C overnight.
3.3.10 Over-production and purification of Strep-tag fusion
proteins from pASK-IBA vectorsDuring this work, several chlamydial genes were cloned in pASK-IBA vectors, whichadd a Strep-tag to the cloned protein. Based on the binding selectivity of Strep-tag to Strep-Tactin, Strep-Tactin sepharose (IBA-BioTAGnology) was used to purify recombinantproteins under physiological conditions. After application of cleared cell lysate on Strep-Tactin column and washing steps, the recombinant protein was eluted with lowconcentration of desthiobiotin (2.5 mM).
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3.3.10.1 Over-production and purification of cytoplasmic fusion
proteins Strep-tagged MreB and Strep-tagged MurF from
C. pneumoniaeThe expression strain E. coli BL21 (DE3) was transformed with pASK-IBA3-mreB orpASK-IBA5-murF plasmids. A preculture was prepared in LB medium supplemented with100 mg/l ampicillin and incubated in shaking water bath (GFL) at 30°C overnight.Expression culture was prepared using 2% (v/v) inoculum from the preculture in fresh LBmedium supplemented with 100 mg/l ampicillin. The expression culture was incubated inshaking water bath at 30°C until OD600 of 0.5-0.6. Anhydrotetracycline (200 ng/ml) wasadded to induce the recombinant protein production. Culture was incubated in shakingwater bath at 20°C for 20 hours. Cells were harvested by centrifugation (Sorvall EvolutionSuperspeed, rotor: SLC-6000, 7000 rpm, 15 min, 4°C). Cell pellets were stored at -20°C untilused for preparation of cleared lysate.All buffers used for the purification of the Strep-tagged proteins are listed with theircomposition in Table 13. Cleared lysate was prepared by allowing frozen cells to thaw onice for 15 minutes. Cell pellet from 1 liter culture was resuspended in 10 ml buffer W. Cellsuspension was sonicated for 10 cycles of 20 seconds separated by 1 minute break on iceusing Ultrasonic homogenizer UP50H (Branson). DNase I (20 mg/l) and RNase A (20 mg/l)were added and suspension was incubated on ice for 15 minutes, .then centrifuged(Heraeus, rotor: 3746, 13500 rpm, 30 minutes, 4°C). The clear supernatant, which containsthe soluble proteins, was separated from the insoluble cell components.All the following steps for protein purification were performed at 4°C. The clearedlysate was added to a pre-equilibrated Strep-Tactin column, where the fusion proteincontaining Strep-tag could bind to the Strep-Tactin sepharose. The column was washed 5times with 1 column bed volume (CV) of buffer W to remove non-specifically boundproteins to the Strep-Tactin. Finally, the Strep-tagged protein was eluted with 3 CV of bufferE and collected in 0.5 CV fractions. The Strep-Tactin column was regenerated using 10 CV ofbuffer R.
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Table 13: Buffers used for purification of Strep-tagged proteins
Buffer CompositionBuffer W (lysis and wash buffer) 100 mM Tris/HCl pH8.0, 150 mM NaCl, 1 mM EDTABuffer E (elution buffer) 100 mM Tris/HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 2.5mM desthiobiotinBuffer R (regeneration buffer) 100 mM Tris/HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 1mM hydroxy-azophenyl-benzoic acid (HABA)
3.3.10.2 Over-production and purification of Strep-tagged PBPs from
C. pneumoniaeAll the steps for the over-production of Strep-tagged PBPs from C. pneumoniae werethe same as described in section 3.3.10.1 with some modifications. Several incubationtemperatures for the overnight culture and the expression culture were tried (20°C, 25°C,30°C and 37°C). Induction was performed over different periods of incubations (3 hours, 5hours and 20 hours). Induction was started at different OD600 (0.4, 0.5, and 0.6).Some modifications were introduced to the steps for the preparation of the clearedlysate described in section 3.3.10.1. Having a predicted membrane anchor, PBPs wereexpected to need detergents to be dissolved. Buffer W containing different concentrationsof one or two detergents (triton x100, sodium lauroylsarcosine, DDM, CHAPS, and tween20) were tried to prepare the cleared lysate.
3.3.11 Over-production and purification of His-tag fusion
protein from pET-21b and pET-52b vectorsDuring this work, chlamydial genes encoding MreB, PBPs, MurF, and GlyA werecloned in pET-21b and/or pET52b vector(s), which introduce(s) a His-tag at the C-terminalof the cloned protein. The His-tag facilitates the protein purification by binding toimmobilized metal chelate affinity chromatography based on Ni2+ or Co2+ ions such as Ni-NTA or TALON resins respectively. After washing steps with buffer containing low
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3.3.11.1 Over-production and purification of MreB-His6 and C345A
MreB-His6mutant from C. pneumoniaeThe plasmid pET-21b-mreB was transformed into E. coli BL21 (DE3). A preculturewas prepared in LB medium supplemented with 100 mg/l ampicillin. The culture wasincubated in a shaking water bath (GFL) at 30°C overnight. The expression culture wasprepared using 2% (v/v) inoculum of the preculture in a fresh LB medium supplementedwith 100 mg/l ampicillin. The expression culture was incubated in shaking water bath at30°C until OD600 of 0.5-0.6. IPTG (0.5 mM) was added to induce the recombinant proteinproduction. Culture was incubated in shaking water bath at 20°C for 4-5 hours. Cells wereharvested by centrifugation (Sorvall Evolution Superspeed, rotor: SLC-6000, 7000 rpm, 15min, 4°C). Cell pellet were stored at -20°C until used for preparation of cleared lysate.All buffers used for the purification of the His-tagged proteins are listed with theircomposition in Table 14. Cleared lysate was prepared by allowing frozen cells to thaw onice for 15 minutes. Cell pellet of 1 liter culture was resuspended in 10 ml lysis buffer, andlysozyme was added to a final concentration of 0.5 mg/ml. Cells were allowed to lyse atroom temperature for 30 minutes. Cell suspension was sonicated for 6 cycles of 15 secondsseparated by 1 minute break on ice using Ultrasonic homogenizer UP50H (Branson). DNaseI (20 mg/l) and RNase A (20 mg/l) were added and suspension was incubated on ice for 15minutes. The suspension was then centrifuged (Heraeus, rotor: 3746, 13500 rpm, 30minutes, 4°C). The clear supernatant, which contains the soluble proteins, was separatedfrom the insoluble cell components.All the following steps for protein purification were performed at 4°C. The clearedlysate from 1 liter culture was mixed with 1 ml pre-equilibrated Ni-NTA resin andincubated with mild shaking at 4°C for 1 hour. The Ni-NTA resin was packed in gravity flowcolumn, washed with 5 ml of wash buffer 1 followed by 5 ml of wash buffer 2. His-taggedprotein was eluted using 3 ml of elution buffer and collected in 0.5 ml fractions.
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Table 14: Buffers used for the purification MreB-His6
Buffer CompositionLysis buffer 50 mM Tris/HCl pH 8, 300 mM NaClWash buffer 1 50 mM Tris/HCl pH 8, 300 mM NaCl, 10 mM imidazoleWash buffer 2 50 mM Tris/HCl pH 8, 300 mM NaCl, 20 mM imidazoleElution buffer 50 mM Tris/HCl pH 8, 300 mM NaCl, 250 mM imidazole
3.3.11.2 Over-production and purification of MurF-His6 from
C. pneumoniaeAll steps for the over-production of His-tagged MurF from C. pneumoniae are thesame as described in section 3.3.11.1.Due to the formation of inclusion bodies, the His-tagged protein was purified fromthe pellet remaining after preparation of the cleared lysate as described in section 3.3.11.1.The pellet was washed with 10 ml lysis buffer, then resuspended in 10 ml lysis buffercontaining 0.5% (w/v) sodium lauroylsarcosine, incubated on ice for 15 minutes withvortexing in between, followed by centrifugation (Heraeus, rotor: 3746, 13500 rpm, 30minutes, 4°C). The clear supernatant, which contains the His-tagged protein, was separatedfrom the insoluble components.The protein purification steps are the same as described in section 3.3.11.1 usingbuffers listed in Table 15.After purification, MurF was used directly for co-pelleting assay with MreB or mixedwith 98% glycerol until a final concentration of 20% (v/v) and stored at -20°C.
Table 15: Buffers with sodium lauroylsarcosine used for His-tagged protein
purification
Buffer CompositionLysis buffer 50 mM sodium phosphate buffer pH 7.5, 300 mM NaClWash buffer 1 50 mM sodium phosphate buffer pH 7.5, 10 mM imidazole, 0.5%(w/v) sodium lauroylsarcosine
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Buffer CompositionWash buffer 2 50 mM sodium phosphate buffer pH 7.5, 20 mM imidazole, 0.5%(w/v) sodium lauroylsarcosineElution buffer 50 mM sodium phosphate buffer pH 7.5, 250 mM imidazole, 0.3%(w/v) sodium lauroylsarcosine
3.3.11.3 Over-production and purification of His-tagged PBPs from
C. pneumonaieThe plasmid pET-21b-PBP2, -PBP3, or -dacF was co-transformed with chaperoneplasmid pKJE7 (TaKaRa) into E. coli BL21 (DE3). pKJE7 plasmid (Figure 15) encodes threechaperone proteins DnaK, DnaJ and GrpE. Chaperones have been demonstrated to beinvolved in protein folding process and preventing protein aggregation. Co-expression of atarget protein with chaperones was shown to increase the recovery of expressed proteinsin the soluble fraction[127].
Figure 15: Chaperone plasmid pKJE7 (TaKaRa)A preculture was prepared in LB medium supplemented with 100 mg/l ampicillinfor the selection of pET-21b plasmid and 30 mg/l chloramphenicol for the selection ofpKJE7 chaperone plasmid. The culture was incubated in a shaking water bath (GFL) at 30°Covernight. The expression culture was prepared using 2% (v/v) inoculum of the preculturein a fresh LB medium supplemented with 100 mg/l ampicillin, 30 mg/l chloramphenicoland 2 g/l L-arabinose for the expression of the chaperone proteins. The expression culture
Materials and Methods 52was incubated in shaking water bath at 30°C until OD600 of 0.4-0.5. IPTG (0.5 mM) wasadded to induce the recombinant protein production. Culture was incubated in shakingwater bath at 20°C for 5 hours. Cells were harvested by centrifugation (Sorvall EvolutionSuperspeed, rotor: SLC-6000, 7000 rpm, 15 min, 4°C). Cell pellet were stored at -20°C untilused for preparation of cleared lysate.Being in the insoluble fraction after the preparation of the cleared lysate, His-taggedPBPs were recovered and purified on Ni-NTA resin using sodium lauroylsarcosine asdescribed in section 3.3.11.2.The purified His-tagged PBPs were mixed immediately with 98% glycerol (1:1) andstored at -20°C.
3.3.11.4 Over-production and purification of His-tagged GlyA from
C. pneumoniaeThe plasmid pET-21b-glyA was transformed into E. coli BL21 (DE3). All the steps forover-production and protein purification are the same as described in section 3.3.11.1. Allbuffers (Table 16) used for purification were supplemented with 5 mM β-mercaptoethanol,0.1 mM pyridoxal phosphate and 25% (w/v) glycerol to increase the stability of GlyAduring purification.At the end of purification steps, His-tagged GlyA elution fractions were storeddirectly at -20°C.
Table 16: Buffers used for the purification of His-tagged GlyA
Buffer CompositionLysis buffer 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 5 mM β-mercaptoethanol, 0.1 mM pyridoxal phosphate, 25% (w/v) glycerolWash buffer 1 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 10 mMimidazole, 5 mM β-mercaptoethanol, 0.1 mM pyridoxal phosphate,25% (w/v) glycerolWash buffer 2 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 20 mMimidazole, 5 mM β-mercaptoethanol, 0.1 mM pyridoxal phosphate,25% (w/v) glycerol
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Buffer CompositionElution buffer 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 250 mMimidazole, 5 mM β-mercaptoethanol, 0.1 mM pyridoxal phosphate,25% (w/v) glycerol
3.3.11.5 Purification of His/Strep-tagged GlyA from C. pneumoniaeThe plasmid pET-52b-glyA was transformed into E. coli BL21 (DE3). All the steps forover-production are the same as described in section 3.3.11.1.Protein was first purified based on its His-tag as described in section 3.3.11.4.Elution fractions containing the recombinant GlyA protein were pooled and loaded on agravity flow column containing pre-equilibrated Strep-Tactin sepharose resin. Column waswashed 5 times with 1 CV washing buffer (150 mM Tris/HCl pH 8, 150 mM NaCl, 5 mM β-mercaptoethanol, 0.1 mM pyridoxal phosphate, 25% glycerol). Protein was eluted with 3CV washing buffer containing 2.5 mM desthiobiotin.
3.3.12 Protein buffer exchangeFor the removal of salts, detergents and exchange of protein buffers, Slide-A-Lyzerdialysis cassettes (Thermo Fisher Scientific) and ZebaTM spin desalting columns (ThermoFisher Scientific) were used according to the manufacturer's instructions.Slide-A-Lyzer is based on the principle of dialysis, in which small molecules and ionsin solutions can pass through a semi-permeable membrane in the direction from highconcentration to low concentration. On the other hand, high molecular weight moleculeslike proteins cannot pass through the membrane and remain within the cassette.Zeba spin desalting columns are based on size exclusion chromatography resin, inwhich macromolecules as proteins can pass fast through the column while small moleculesand ions are retained within the columns.
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3.3.13 Analysis of the purified proteins
3.3.13.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)SDS-PAGE is a widely used technique to separate proteins according to their sizeusing electric field. This can be achieved by using the strong anionic detergent sodiumdodecyl sulfate (SDS) to linearize the protein by removing secondary and tertiary proteinstructures. Moreover, SDS uniformly covers the protein conferring it negative electriccharge proportional to its size. Because charge per mass ratio is same among SDS-denatured protein, electrophoretic mobility of proteins in polyacrylamide gels will dependonly on protein size or mass [128].During this work, Pierce protein gels (Thermo Fisher Scientific) with 4-12% and 4-20% polyacrylamide gel gradient were used according to the manufacturer's instructions.Protein samples were first mixed with LDS sample buffer (4X). To break the possibledisulfide bridges in the protein, dithiothritol (DTT) was added. The reaction mix washeated for 5 minutes at 95° in water bath (Julabo). For the analysis of separated proteins,Protein Marker Broad Range (NEB) and Novex Sharp Pre-stained Protein Standard(Invitrogen) were used during this work. Electrophoresis was performed using NovexMini-Cell (Invitrogen) at 170 Volts for 55 minutes in Tris-HEPES-SDS running buffer. Forstaining of the gel after electrophoresis, PageBlue protein staining solution (Thermo FisherScientific) was used according to the manufacturer's instructions. The gel was first washedwith distilled water for 3 times to remove SDS, and then stained with the protein stainingsolution for 1 hour until overnight with shaking. Finally, the stained gel was washed withdistilled water.
3.3.13.2 Estimation of protein concentrationEstimation of protein concentration was achieved during this work using Bradfordmethod [129]. This method involves the binding of Coomassie Brilliant Blue G-250 toproteins, which results in a shift in the absorption maximum of the dye from 365 nm to 595nm and the increase in the absorption at 595 nm is directly proportional to the sampleprotein content.
Materials and Methods 55During this work, protein estimation was performed in microtiter plates (VWRInternational). Protein samples or bovine serum albumin (BSA) (Sigma-Aldrich) standardsolution (10 µl) were mixed with 40 µl Coomassie Brilliant Blue G-250 (Bio-RadLaboratories) and 160 µl deionized water. Samples were incubated for 10 minutes at roomtemperature and then absorbance at 595 nm was determined using microtiter plate readerNanoQuant (Tecan Group). For protein samples containing high concentrations ofdetergents, which are not compatible with the methods, protein samples were dialyzed ordiluted to remove the detergents or their incompatibility.
3.4 BIOCHEMICALMETHODS
3.4.1 Nucleotide removalTo examine the effect of different types and concentration of ATP and GTP on thepolymerization of chlamydial MreB, the already bound nucleotides were removed bytreating the dialyzed MreB with Dowex resin as follow. Dialyzed MreB was mixed with1/4th its volume with 50% Dowex resin (1X8-400Cl, Sigma-Aldrich) slurry in 10 mMTris/HCl pH 8.0. The reaction was incubated on ice for 15 minutes with vortexing every 2-3minutes, followed by centrifugation for 5 minutes (Heraeus Biofuge 28RS, rotor: 3751,5300 rpm, 4°C). The supernatant was collected in a separate tube. This procedure wasrepeated 3 times to prove complete nucleotide removal.
3.4.2 MreB light scattering assaysMreB in vitro polymerization was investigated using light scattering assays modifiedfrom the one described by Bean an Amann for MreB of Thermotoga maritima (T. maritima)[130]. The standard polymerization reaction consisted of 5 µM MreB, 200 µM ATP, 5 mMMgCl2, 1 mM EGTA, and 10 mM imidazole buffer, pH 7 in a final volume of 800 µl. The non-protein components were mixed. Separately on ice, MreB was mixed with 1/9th volume of10X cation exchange buffer (1 mM MgCl2, 10 mM EGTA) and incubated for 1 minute.Polymerization reaction was initiated by mixing the two solutions together and detected byquantifying the decreases in the percentage of transmission at 400 nm usingNanophotometer (Implen) at room temperature for 15 minutes. All experiments were
Materials and Methods 56performed in triplicate. For A22 inhibition studies, A22 (Merck) was dissolved in DMSO(Sigma-Aldrich) and added to the non-protein part of the polymerization reaction in a finalconcentration of 5, 50 and 300 µM.
3.4.3 MreB sedimentation assaysExperiments followed the protocol of Bean and Amann [130]. MreB (5 µM) waspolymerized under standard conditions in presence or absence of 300 µM A22 for 1 hour at20°C. Polymerized MreB was centrifuged (Heraeus Biofuge 28RS, rotor: 3753, 22000 rpm,49.500 g, 30 minutes 20°C). The pellet was washed twice with the polymerization bufferfollowed by centrifugation. Finally, equivalent volumes of pellet and supernatant wereanalyzed by SDS-PAGE and Coomassie Blue staining.
3.4.4 MreB and MurF co-pelleting assays
In vitro interaction of MreB with MurF was investigated following a previouslydescribed co-pelleting protocol [131]. The sedimentation assays in section 3.4.3 wereperformed with MreB (5 µM) polymerized in presence of different concentrationschlamydial MurF (2.5, 5, 10 and 15 µM). Reactions were incubated for 1 hour at 30°C in awater bath. As a control, MurF (15 µM) was incubated in the reaction buffer without MreBto ensure the non-specific sedimentation of MurF. In another control, MreB (5 µM) wasallowed to polymerize in presence of BSA (15 mM) to ensure the non-specific interaction ofMreB with proteins other than MurF. At the end of incubation time, samples werecentrifuged (Heraeus Biofuge 28RS, rotor: 3753, 22000 rpm, 49,500g, 30 minutes 30°C),washed and analyzed using SDS-PAGE and Coomassie Blue.
3.4.5 Phosphate release assaysTo analyse ATPase activity of MreB, phosphate release using a molybdate malachitegreen assay was investigated. The technique is based on the formation of complex betweenmalachite green and phosphomolybdate under acidic conditions.Wild-type and C345A mutant MreB were incubated with ATP (100 µM) usingstandard polymerizing and non-polymerizing (in the absence of MgCl2, pH 8) conditions.Control reactions without ATP and without MreB were also performed. At different time
Materials and Methods 57intervals, 100 µl aliquots were removed and mixed directly with 5 µl ice cold 70%perchloric acid (Merck) to stop the enzymatic reaction. The reactions were then incubatedon ice for 10 minutes and centrifuged for 5 minutes at 49,500g, 4°C (Heraeus Biofuge28RS). The supernatant was mixed with equal volume of Molybdate Dye Solution(Promega) and incubated in microtiter plate for 30 minutes at room temperature.Absorbance was measured at 600 nm in a microtiter plate reader NanoQuant (TecanGroup). All experiments were carried out in triplicate.
3.4.6 Detection of racemization activity of chlamydial GlyATo investigate the in vitro racemization activity of chlamydial GlyA, a previouslydescribed racemization reaction for GlyA from E. coli was performed [98]. GlyA dialyzedagainst 20 mM BES buffer pH 7.0 (Sigma-Aldrich) containing 0.1 mM pyridoxal phosphatewas mixed in 40 µl reaction volume with 25 mM L-alanine or 1 mM D-alanine, 0.03 mMpyridoxal phosphate and 1 mM DTT in 50 mM BES buffer pH 7.5. The reaction wasincubated at 37°C overnight. Control reactions without amino acid or without GlyA werealso performed.D-alanine produced or consumed by the expected racemization activity on L- or D-alanine respectively were detected using a fluorescent-coupled enzyme assay [132]. Thisassay based on oxidizing D-alanine into pyruvate, ammonia and hydrogen peroxide usingthe activity of D-amino acid oxidase (DAO) followed by quantitative detection of releasedhydrogen peroxide using fluorescent substrate QuantaBlu. Its oxidized form has anexcitation wavelength of 325 nm and emission wavelength of 420 nm.
Figure 16: Fluorescent-coupled enzyme assay reactions for detection of D-alanine
[132]
Materials and Methods 58A detection buffer for D-alanine was prepared containing 10 µl QuantaBlu substrate(Thermo Fisher Scientific), 2.78 µg/ml FAD, 1 unit horseradish peroxidase, 0.06 unit DAO,100 mM Tris/HCl pH 8.5 in 360 µl final volume. Each racemization reaction was mixed with360 µl detection buffer and incubated for 1 hour at room temperature. Samples were thenanalyzed using fluorescent spectrophotometer at excitation wavelength 325 nm andemission wavelength 420 nm.
3.4.7 Butanol/pyridine acetate extraction of lipidsLipids can be extracted from reaction mixtures with the help of n-butanol/pyridineacetate [133]. During this work, butanol/pyridine acetate pH 4.2 was added to equalvolume of reaction samples containing lipids. The reaction was vortexed for 1 minute usingVortex Genie (Scientific Industries) and then centrifuged (Eppendorf MiniSpin, 13400 rpm,5 minutes) to separate aqueous and organic phases. The upper phase containing lipids wasthen analyzed using thin layer chromatography (TLC).
3.4.8 Thin layer chromatography for detection of lipidsThin layer chromatography (TLC) can be used for the analysis of lipid extracts. It is aseparation process, in which lipids are separated according to their different solubilities inthe mobile and stationary phases. The lipids are transported by a mobile phase on a silicagel plate (stationary phase). The mobile phase is a non-polar solvent, which moves bycapillary action along the stationary phase. How far the lipids from the mobile phase can betaken along depends on the polarity of the lipids and their interaction with the silica gel.The stronger the interaction of lipids with the mobile phase, the further they aretransported.During this work, silica gel plates 60 with 0.25 mm layer thickness (Merck) wereused. The lipid extracts were spotted onto the plate and dried. The loaded TLC plate wasplaced in a glass chamber (Desaga) with a mobile phase (Table 17) according to the recipeby Rick et al. [134]. The chromatography was allowed to run for 30-50 minutes then theTLC was removed and air-dried. To visualize the lipid bands, the TLC plate was immersedin a phosphomolybdic acid staining solution (PMA) (Table 17) to cover the entire surface,
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Table 17: Solutions used for thin layer chromatography
Solution ContentMobile phase Chloroform, methanol, distilled water.,ammonium-hydroxide [88:48:10:1 (v/v)]Phosphomolybdic acid (PMA) solution 2,5 % (w/v) phosphomolybdic acid and 1%(w/v) ceric-sulfate in 6 % (w/v) sulfuricacid
3.4.9 Testing the transpeptidase activity of chlamydial PBP2
and PBP3
3.4.9.1 Preparation of peptidoglycan sacculi from E. coliIn a transpeptidation reaction catalyzed by PBPs, the newly synthesized cell wallmaterials are attached to cell wall via a peptide bond. Therefore, to test the transpeptidaseactivity of the chlamydial PBP2 and PBP3 using their natural substrates, both the cell wallprecursor, lipid II and PG sacculi should be used in the assay. Two types of PG sacculi ofdifferent bacterial sources were used; PG sacculi from B. subtilis (Sigma-Aldrich) and from
E. coliW3110 (prepared during this work).LB medium (1 liter) was inoculated with 1% (v/v) E. coli W3110 preculture andincubated at 37°C until OD600 of 0.5-0.6. Cells were harvested by centrifugation (SorvallEvolution Superspeed, rotor: SLC-6000, 7000 rpm, 15 min, 4°C). The pellet wasresuspended in 20 ml PBS buffer (8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4 2H2O, 0.24 g/lKH2PO4) and poured on 80 ml of boiling SDS solution (5% w/v) with stirring. The mixtureis allowed to boil for 30 minutes then incubated at room temperature overnight to allowcomplete cell lysis and release of murein sacculi. Separation of the sacculi was achieved bycentrifugation (Heraeus, rotor: 3764, 13500 rpm, 30 minutes, 25°C). The pellet was washed3-4 times with distilled water to remove SDS. The pellet is then resuspended in 1 ml PBSbuffer and digested overnight at 37°C with α-chymotrypsin (300 µg/ml final concentration)to break down proteins. On the next day, another 300 µg/ml were added and reaction was
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3.4.9.2 Testing transpeptidase activity using natural substrates, lipid
II and PG sacculiBorn et al. [106] showed that transpeptidase domain of bi-functional PBP1a from
E. coli is not able to show in vitro activity in absence of a functional transglycosylasedomain. Based on these results, mono-functional transpeptidases such as PBP2 and PBP3from C. pneumoniae cannot exhibit activity disconnected from transglycosylation. For thisreason PBP2 mutant from Staphylococcus aureus, a bi-functional PBP, with a functionaltransglycosylase domain and a mutated dysfunctional transpeptidase domain, was addedto the assay.PBP2 or PBP3 from C. pneumoniae together with PBP2 mutant from S. aureus weremixed with PG sacculus in a buffer containing 25 mM Tris/HCl pH 7.5, 10 mM MgCl2, 100mM NaCl, 0.05% Triton X-100. The reaction volume was adjusted to 30 µl and incubated onice for 10 minutes. Lipid II (2 nmol dissolved in 0.05% Triton X-100) was added and thereaction was incubated at 30°C for 2 hours. Samples were centrifuged (EppendorfMiniSpin, 13400 rpm, 10 minutes) to remove the PG sacculus and lipid II in the supernatantwas detected by TLC.
3.4.9.3 Testing transpeptidase activity using artificial thioester S2d
substrateThioester analogs of D-alanyl-D-alanine moiety of the bacterial cell wall stempeptide have long been used to study the transpeptidation reactions catalyzed by penicillinbinding proteins [135-137]. The use of such chromogenic substrates facilitates thedetection of the reaction by measuring the absorbance at 254 nm. Coupling of the releasedproduct to 4,4’-dithiopyridine increases the sensitivity of the assay by 15 folds. In presence of4,4’-dithiopyridine, the increase of the reaction absorbance at 325 nm is used as a measure forthe transpeptidase activity.
Materials and Methods 61The thioester N-benzoyl-D-alanylmercaptoacetic acid (S2d) (Figure 17) was suppliedkindly by Prof. Dr. Piel (University of Bonn, Germany). A stock solution of S2d substrate wasprepared by dissolving the substrate in 100 µL DMSO, then add 10 mM sodium phosphatebuffer pH 7 to reach the final concentration (10 mM). PBPs were dialyzed against 10 mMsodium phosphate buffer pH 7.0 or 10 mM tris buffer pH 7.5 containing 10% DMSO (v/v) and500 mM NaCl. PBP2 or PBP3 from C. pneumoniae was mixed with 1 mM S2d and 0.8 mM 4,4’-dithiopyridine in presence or absence of DMSO (10% v/v). The reaction was incubated at 37°Cfor 1 hour with absorbance at 325 nm measured every 10 minutes using Nanophotometer(Implen).
Figure 17: Chemical structure of the thioester N-benzoyl-D-alanylmercaptoacetic acid
(S2d).
3.4.10 Testing the DD-carboxypeptidase activity of
chlamydial PBP6aDD-carboxypeptidases are capable of removing the terminal D-alanine from thestem peptide of PG resulting in tetrapeptide side chain which cannot be cross-linked bytranspeptidases [104]. To detect the DD-carboxypeptidase activity of PBP6a, two differentsubstrates were tested.
3.4.10.1 Lipid II as a substrate for PBP6aIn this assay, PBP6a (1 µg) was added to 2 nmol of lipid II dissolved in 0.1% triton in30 µl reaction containing 100 mM NaCl, and 50 mM Tris/HCl pH 7.5. The reaction wasincubated 3 hours or overnight. At the end of the incubation time, the reaction lipid contentwas analyzed by TLC. The release of the terminal D-alanine was expected to show adifference in the mobility during TLC analysis.
Materials and Methods 62
3.4.10.2 Nα,Nε-diacetyl-L-lys-D-ala-D-ala as a substrate for PBP6aThis assay was described previously by Gutheil et al. [132]. PBP6a (1 µg) was mixedwith 1 mM of the artificial substrate Nα,Nε-diacetyl-L-lys-D-ala-D-ala (Sigma-Aldrich) in 40µl of 100 mM Tris/HCl pH 7.5, 0.5 mg/ml BSA, 100 mM NaCl and 150 pmol D-alanine. Thereaction was incubated at 30°C for 3 hours overnight. The released D-alanine was detectedusing the fluorescent-coupled enzyme assay described in section 3.4.6
3.5 BACTERIAL ADENYLATE CYCLASE TWO-HYBRID SYSTEM
ASSAYSThe bacterial adenylate cyclase two-hybrid system (BACTH) allows the in vivoinvestigation of protein-protein interactions. The principle of the assay based on theinteraction mediated reconstitution of active adenylate cyclase enzyme [138]. The catalyticdomain of the adenylate cyclase enzyme from Bordetella pertussis consists of twofragments, T25 and T18 [139]. When both fragments are separated, the protein is notactive. Fusion of the two fragments to two interacting proteins results in a functionalcomplementation between T25 and T18 fragments and, therefore, cAMP is produced.Binding of the latter to the catabolite activator protein (CAP) regulates gene transcriptionin E. coli. Genes of lac and mal operons are expressed and higher β-galactosidase activitycan be detected.
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Figure 18: Schematic presentation of BACTH system.(A) The recombinant plasmids constructed to fuse the T25 and T18 to test proteins. (B) Theprinciple of BACTH system. CAP = catabolite activator protein.
3.5.1 Detection of BACTH system protein-protein interaction
using β-galactosidase assayDuring BACTH system assays, protein-protein interaction is associated withincrease in the β-galactosidase activity, which can be measured quantitatively using a β-galactosidase assay.
Materials and Methods 64Buffers and solutions required for the β-galactosidase assay are listed in Table 18.The two recombinant BACTH plasmids pKNT25 (or pKT25) and pUT18 (or pUT18C) wereco-transformed into adenylate cyclase deficient E. coli strain BTH101. Empty BACTHvectors and pKT25zip/pUT18Czip were co-transformed in the same strains as negative andpositive controls respectively. Three different clones of each transformation were used totest the β-galactosidase activity. Each clone was used to infect 3 ml of the minimal mediumM63 containing 25 µg/ml kanamycin and 50 µg/ml ampicillin to prepare the preculturesthat were incubated at 37°C overnight in a rotary incubator (Heraeus). The precultures (30µl) were used to infect another 3 ml of M63 medium containing 0.5 mM IPTG, 25 µg/mlkanamycin and 50 µg/ml ampicillin. The cultures were incubated under the sameconditions. Daily, 350 µl aliquots were taken and incubated on ice for 30 minutes thendiluted with 1400 µl M63 medium. The OD600 of the diluted cultures was measured andsodium lauroylsarcosine (2% end concentration) was added to the rest of the dilutedcultures and incubated at 30°C to induce cell lysis. The reaction was diluted with equalvolume of Z buffer (Table 18) and incubated at 30°C for 5 minutes. To 1 ml of the dilutedreaction, 250 µl O-nitrophenyl-β-D-galactoside (ONPG) was added. β-galactosidasehydrolyzed the synthetic substrate ONPG with the production of the yellow coloredproduct O-nitrophenol. The reaction was stopped with 500 µl stop solution and absorbanceat 420 nm was measured. When ONPG is in excess, the production of o-nitrophenol per unittime is proportional to the activity of β-galactosidase; thus, the production of yellow colorcan be used to quantify the enzyme activity, which is expressed as Miller units calculatedwith the following formula: = 1000 ∗∗ ∗T = time between addition of ONPG and reaction stopV = culture volume in ml
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Table 18: Solutions required for β-galactosidase assay
Solution ContentM63 minimal medium 2 g/l (NH4)2SO4, 13.4 g/l KH2PO4, 0.5 mg/lFeSO4 7H2O, pH 7. After autoclaving, filtersterilized 1 ml MgSO4 (1M), 10 ml glucose(20% w/v) and 2 ml thiamine HCl (0.05%)are addedZ buffer 0,06 M Na2HPO4·2H2O, 0.04 MNaH2PO4·2H2O, 0.01 M KCl, M 0.001 MMgSO4ONPG solution 4 mg/ml in distilled waterStop solution 1 M Na2CO3
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4 RESULTS
4.1 FUNCTIONAL ANALYSIS OF THE CHLAMYDIAL ACTIN HOMOLOG
MREBAll bacteria in the family Chlamydiaceae lack the essential cell division protein FtsZ,but harbor, despite of their spherical shape, the actin homolog MreB. The role of thecytoskeletal protein in such endobacteria is not known. It was shown recently thatmaintaining lipid II biosynthesis in cell wall-less bacteria reflects an essential role of thelipid II biosynthesis pathway for prokaryotic cell division [95]. MreB could be involved inmaintaining coordinated cell division via tethering lipid II biosynthesis to the chlamydialseptum.
4.1.1 Cloning, over-production and purification of chlamydial
MreBThe mreB gene from C. pneumoniae was cloned in the expression vectors, pASK-IBA3 and pET-21b (done by Christian Otten). The pASK-IBA3-mreB construct introduces aC-terminal Strep-tag, while the pET-21b-mreB one fuses a C-terminal His-tag (Figure 19)
Figure 19: Schematic presentation of the recombinant plasmids pASK-IBA3-mreB (A)
and pET-21b-mreB (B)
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4.1.2 Over-production and purification of chlamydial MreBThe Strep-tagged MreB was purified from 1 liter culture after overnight inductionusing 200 ng/ml anhydrotetracycline. The cleared lysate was loaded on a Strep-Tactincolumn. After washing steps, Strep-tagged protein was eluted with a buffer containing 2.5mM desthiobiotin (section 3.3.10.1). The over-production of His-tagged MreB was inducedwith 0.5 mM IPTG for 4-5 hours. The cleared lysate was purified on Ni-NTA column. TheHis-tagged protein was eluted with a buffer containing high concentration of imidazole(200-250 mM) (section 3.3.11.1).In this project, both MreB-Strep and MreB-His6 were successfully purified (Figure20) but the purity and the overall yield of the MreB-His6 were significantly higher, thelatter may be a result from different strengths of the tetA and T7 promoters. Hence, therecombinant His-tagged protein was used to analyze the activity of MreB from
C. pneumoniae.
Figure 20: SDS-PAGE of purification of MreB-Strep (A) and MreB-His6 (B)Marker: protein marker (Broad Range 2-212 KDa, NEB)
4.1.3 Investigation of chlamydial MreB polymerization in vitroTo examine the functionality of MreB, the ability of the protein to polymerize in vitrowas tested under different conditions of pH, Mg2+ concentration and K+ concentration asdone recently for MreB from T. maritima (MreB1) [130] and B. subtilis [140].Chlamydial MreB polymerized in vitro in light scattering (Figure 21) andsedimentation assays (Figure 22 B). The rate and extent of polymerization were favored atslightly acidic pH values and in presence of Mg2+ ions but inhibited by K+ ions (Figure 21 A-
Results 68C). The chlamydial protein showed more similarity to MreB from B. subtilis than to MreBfrom T. maritima regarding its pH and K+ dependence. Polymerization of MreB from
C. pneumoniae and B. subtilis was greatly impaired or completely inhibited at pH values ≥ 8and strongly inhibited at KCl concentrations of 20 mM or higher [140]. In contrast, MreBfrom T. maritima was shown to polymerize at pH as high as 9.5 and in presence of 20 mMKCl [130]. These properties probably reflect the adaptation of this extremophilic organismto geothermally heated marine sediments.
Figure 21: Polymerization of wild-type MreB from C. pneumoniae.
In vitro light scattering assays were performed at varying pH (A) MgCl2 (B) and KCl (C)concentrations using 5 µM chlamydial MreB
4.1.4 Investigation of the effect of S-(3,4-dichlorobenzyl)
isothiourea (A22) on the in vitro polymerization of MreBS-(3,4-dichlorobenzyl)isothiourea (A22) was firstly defined as a compound thatinduces spherical cells in E. coli [141]. A22 is now used to disrupt the cell cycle-related
Results 69reorganization of the MreB cytoskeleton in vivo causing its disassembly with consequentloss of rod shape and cell death [68, 142]. The compound impairs the ATP dependantpolymerization of T. maritima MreB in vitro by competitive binding into the nucleotide-binding pocket of the protein [143].The effect of A22 on the in vitro polymerization of MreB form C. pneumoniae wasinvestigated using light scattering and sedimentation assays. Both experiments revealedthat A22 did not impair the polymerization of chlamydial MreB in vitro (Figure 22).
Figure 22: Influence of A22 on the polymerization of chlamydial MreB.The effect of A22 on MreB wild-type and C345A mutant polymerization was determined by lightscattering (A) and sedimentation assays (B). For sedimentation assays, polymerized MreB wascentrifuged and equivalent volumes of pellet (P) and supernatant (S) were separated by SDS-PAGE
4.1.5 Preparation of C345A MreB mutantIn a previous study [68], A22 selection pressure was used to generate seven A22-resistant stable mutants from C. crescentus. Sequence analysis of all mutants showed aminoacid exchanges in MreB in residues that were conserved in MreB from C. crescentus,
T. maritima, and E. coli (Figure 23A). Five of the seven exchanges were located in thenucleotide-binding pocket and the last two were present in a helix that contacts thenucleotide. Interestingly, one of these altered residues in mutant C. crescentus MreB isintrinsically exchanged in wild-type MreB from C. pneumoniae (Ala345 located in helix 12is replaced by cysteine, numbering of C. pneumoniae) (Figure 23B).
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Figure 23: Schematic presentation of amino acid exchange map in MreB from A22-
resistant C. crescentus mutants (A) [68] and intrinsically exchanged residue 345 in
MreB from C. pneumoniae (B).To test whether this natural alteration in chlamydial MreB is responsible forresistance to A22, Cys345 was replaced with alanine to restore the conserved residue in
C. crescentus, T. maritima, B. subtilis and E. coli. With the help of site-directed mutagenesis,C345A MreB mutant was successfully prepared and the desired mutation was confirmed bysequencing.
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4.1.6 Over-production and purification of C345A MreB mutantC345A MreB-His6 mutant was successfully over-produced and purified using thesame protocol described for the wild-type MreB-His6 (Figure 24).
Figure 24: SDS-PAGE of C345A MreB-His6mutant purification from C. pneumoniae.Marker: protein marker (Broad Range 2-212 KDa, NEB)
4.1.7 Studies on the effect of A22 on the in vitro polymerization
of C345A MreB mutantTo examine whether this intrinsic exchange of amino acid residue 345 in wild-typeMreB is responsible for its resistance to A22, the effect of A22 on the in vitropolymerization of C345A MreB was investigated using light scattering and sedimentationassays. Interestingly, the C345A mutant showed the same phenotype like the wild-typeMreB protein and its polymerization was not affected by A22 (Figure 22).
4.1.8 Detection of the effect of nucleotides on MreB wild-type
and C345A mutant polymerization in vitroTo further analyze the resistance of chlamydial MreB to A22, the capability of wild-type and C345A MreB mutant to polymerize in the absence of nucleotides was investigated(Figure 25).
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Figure 25: Influence of nucleotides on MreB polymerization.Polymerization of chlamydial wild-type and C345A mutant MreB was investigated in the presenceand absence of ATP (A) and GTP (B) using light scattering assays under standard conditions.Remarkably, both the rate and extent of polymerization of chlamydial MreB wildtype and mutant were nearly similar in the absence or presence of ATP (Figure 25A). Onthe other hand, the polymerization of chlamydial MreB in presence of GTP was impairedconcerning its extent and kinetics. Binding of GTP to the nucleotide-binding pocket ofchlamydial MreB might introduce conformational changes that affect the polymerizationprocess.To exclude that MreB-bound, co-purified ATP might have overcome the need to addexternal ATP to drive the polymerization reaction, MreB wild type and mutant were treatedwith an anion exchange resin prior to use, as described previously for nucleotide exchangeprocedures for MreB [130, 140]. The so treated MreB was still capable of polymerizationwithout the addition of ATP (Figure 26).
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Figure 26: Influence of ATP on MreB polymerization after anion exchange treatment.Polymerization of wild-type and C345A mutant MreB was investigated after the removal of boundnucleotides using Dowex resin.Therefore, it appears reasonable that a competitive inhibitor of nucleotide bindingsuch as A22 cannot block the polymerization of chlamydial MreB proteins. These findingsconcerning ATP independent polymerization are consistent with previous in vitro resultson MreB from B. subtilis which showed that the purified actin homolog polymerized in anucleotide independent fashion [140].
4.1.9 Detection of ATPase activity of wild-type MreB and C345A
mutant in vitroAlthough the polymerization of MreB from B. subtilis is ATP independent, theprotein has ATPase activity [140]. To test whether chlamydial MreB can hydrolyze ATP,phosphate release assays were performed under monomeric and polymeric conditions(Figure 27). Both C345A mutant and wild-type MreB proteins hydrolyzed ATP withoutmarked differences. Applying conditions that hinder MreB polymerization (pH 8.0 andabsence of Mg2+), monomeric MreB hydrolyzed ATP continuously during the whole time ofthe experiment (1 hour). On the other hand, under standard polymerization conditions (pH7.0, Mg2+ 5 mM), ATPase activity was stalled once polymerization was completed (after 15minutes). Additionally, under non-polymerizing conditions MreB released approximately 3
Results 74times more phosphate compared to polymerized MreB. These results indicate that ATPaseactivity is associated with the monomeric stage of MreB.
Figure 27: ATPase activity of wild-type and C345A mutant MreB under monomeric
(A) and polymeric (B) conditions.To check if A22 affects the ATPase activity of MreB, A22 was included in assaysunder polymerizing and non-polymerizing conditions. A22 showed no inhibitory effect onATP hydrolysis in all experiments. This indicates that the compound cannot bind to thenucleotide-binding pocket of both wild-type and C345A mutant MreB.
4.1.10 Investigation of MreB interactions with MurF, MurG
and MraYIn order to understand the role of MreB in cell wall biosynthesis, its interactionswith MurF, MurG and MraY, three key enzymes in lipid II biosynthesis, were examined. Theligase MurF attaches the dipeptide D-ala-D-ala producing MurNAc-pentapeptide. The latteris transferred to the membrane lipid carrier C55-P forming lipid I through the activity ofMraY. Subsequently, MurG adds N-acetylglucosamine to lipid I yielding the finalpeptidoglycan precursor lipid II.
4.1.10.1 Cloning, over-production and purification of chlamydial MurF
4.1.10.1.1 Cloning ofmurF from C. pneumoniae in pASK-IBA5 and pET-21b vectorsThe murF gene was cloned in pASK-IBA5 expression vector to construct N-terminal
Strep-tagged MurF fusion protein (MurF-Strep) and in pET-21b vector to construct a C-terminal His6-tagged MurF fusion protein (His6-MurF) (Figure 28).
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Figure 28: Schematic presentation of the recombinant plasmids pASK-IBA5-murF (A)
and pET-21b-murF (B).RS = restriction site.O/P = operator/promoterThe constructed plasmids were transformed into chemo-competent DH5α-E. colistrain. Positive clones were selected by colony PCR (Figure 29) and correctness of theinserted gene was confirmed by sequencing.
Figure 29: Detection of positive clones from recombinant plasmids pASK-IBA5-murF
(A) and pET-21b-murF (B) using restriction analysis and agarose gel electrophoresis.One mg of plasmid DNA was restricted for 1 hour with SacII/NcoI (A) or NheI/NotI (B). DNA ladder:1 Kb DNA ladder (Fermentas)
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4.1.10.1.2 Over-production and purification of chlamydial MurF
Strep-tagged MurF was purified from 1 liter culture after overnight induction using200 ng/ml anhydrotetracycline. The cleared lysate was loaded on Strep-Tactin columns.After washing steps, the Strep-tagged protein was eluted with a buffer containing 2.5 mMdesthiobiotin (section 3.3.10.1). His-tagged MurF was purified from 1 liter culture afterinduction (4-5 hours) with 0.5 mM IPTG. The cleared lysate, prepared with the help of 0.5%(w/v) sodium lauroylsarcosine to solubilize inclusion bodies, was loaded on Ni-NTAcolumn. After washing steps, the His-tagged protein was eluted with a buffer containinghigh concentration of imidazole (200 mM) (sections 3.3.11.1 and 3.3.11.2).During this work, both Strep-MurF and MurF-His6 were successfully purified. Thepurity of the Strep-tagged protein was better but the yield of the MurF-His6 wassignificantly higher (Figure 30). Therefore, the MurF-His6 was used in the interactionassays.
Figure 30: SDS-PAGE showing purification of Strep-MurF (A) and MurF-His6 (B) from
C. pneumoniae.Marker: protein marker (Broad Range 2-212 KDa, NEB)Marker 2: Novex Sharp Pre-stained Protein Marker (Invitrogen)
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4.1.10.2 Investigation of chlamydial MreB interaction with MurF
in vitroMreB was tested for interactions with the cytoplasmic ligase MurF using a co-pelleting assay. MreB was polymerized in presence of the MurF. After centrifugation,equivalent volumes of the pellet and supernatant were analyzed using SDS-PAGE.MurF co-pelleted with MreB polymers but did not sediment or pellet on its own(Figure 31). To confirm the assay specificity, a control containing BSA and MreB showedthat BSA remained in the supernatant and did not interact with MreB in a non-specificmanner. Keeping a constant concentration of MreB (5 µM), the amount of MreB spun downin the pellet was increased with increasing the concentration of MurF (2.5 µM, 5 µM, 10 µMand 15 µM). Almost all MreB was polymerized and recovered in the pellet at a molar ratioof 1:3 (MreB:MurF). These results indicate that polymerization of MreB is favored in thepresence of MurF.
Figure 31: In vitro interaction of MreB and MurF from C. pneumoniae in co-pelleting
assays.MreB was polymerized in the absence and presence of increasing amounts of MurF. Aftercentrifugation, equivalent volumes of supernatants (S) and pellets (P) were separated by SDS-PAGE
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4.1.10.3 Studies on the in vivo interaction between chlamydial MreB,
MraY and MurG proteinsDuring this study, a bacterial adenylate cyclase two-hybrid system (BACTH system,Euromedex) was used to analyze the interaction between MreB and the enzymes catalyzingthe membrane bound steps of lipid II biosynthesis, MraY and MurG in vivo. In this assay,genes of interest were cloned into pUT18 and pKNT25 vectors in frame with genefragments T18 and T25. The two recombinant plasmids were co-transformed into theadenylate cyclase deficient reporter strain E. coli BH101. Interaction between proteinsfused to the two fragments (T18 and T25) mediates the reconstitution of active adenylatecyclase, which produces cyclic AMP (cAMP) and activates the lac and mal operon toproduce β-galactosidase. A β-galactosidase assay was used to quantify the functionalcomplementation of adenylate cyclase enzyme mediated by the interaction between twoproteins.Bacterial two-hybrid analyses showed that MreB is self-interacting confirming theresults from the in vitro polymerization assays. Additionally, MreB showed interaction withboth the integral protein MraY and the membrane associated cytosolic protein MurG. Arelatively low β-galactosidase activity was expected from these assays because of the N-terminal localization of the adenylate cyclase fragments. In fusion with MraY, the adenylatecyclase fragment was located in the periplasm (predicted from topology studies [46] andusing topology prediction program TMHMM [144]). Fused to MurG, the respectivefragment was located closed to the membrane association site of the protein (predictedfrom crystal structure [145]).
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Figure 32: Bacterial two hybrid studies on in vivo interactions between chlamydial
MreB, MraY and MurG.Protein interactions were quantitatively determined by measuring β-galactosidase activities ofthree individually selected replicate co-transformants. The β-galactosidase activities are expressedin Miller Units (change in A420/min/ml/OD600) as mean values (± standard deviation). Unpaired t-test revealed statistical significance in comparison to empty vector negative control (T25×T18), *:two-tailed p-value≤0.05, *** two-tailed p-value≤0.001).
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4.2 ANALYSIS OF CHLAMYDIALGLYA RACEMASE ACTIVITYThe terminal dipeptide D-ala-D-ala of the pentapeptide side chain of lipid II is thetarget for the PBPs activity. Chlamydial genomes lack the alr gene encoding an alanineracemase that is responsible for D-alanine synthesis in other bacteria. It has been shownbefore that GlyA from E. coli can catalyze the interconversion between D- and L-alanine[98]. The racemase activity of chlamydial GlyA was investigated to check whether it couldsynthesize D-alanine in these endobacteria.
4.2.1 Cloning, over-production and purification of chlamydial
GlyAThe pET-21b and pET-52b vectors were used to construct a GlyA with C-terminalHis6-tag and GlyA with both C-terminal His6-tag and N-terminal Strep-tag respectively(Figure 33). Positive clones were selected by colony PCR and were confirmed by restrictionreactions (Figure 34).
Figure 33: Schematic presentation of the recombinant plasmids pET-21b-glyA (A)
and pET-52b-glyA (B).RS = restriction site.
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Figure 34: Detection of positive clones from recombinant plasmids pET-21b-glyA (A)
and pET-52b-glyA (B) using restriction analysis and agarose gel electrophoresis.One mg of plasmid DNA was restricted for 1 hour with NdeI and NotI (A) or SmaI and SacI (B). DNAladder: 1 Kb DNA ladder (Fermentas)
4.2.1.1 Over-production and purification of recombinant GlyAThe His6-tagged GlyA was purified from 1 liter culture after 4-5 hours of inductionwith 0.5 mM IPTG. The cleared lysate was prepared using a buffer containing 5 mM β-mercaptoethanol and 0.1 mM co-factor pyridoxal phosphate to increase the stability ofGlyA. The lysis buffer contained also 25% glycerol to decrease the hydrophobicinteractions between proteins in order to increase the protein purity. The cleared lysatewas loaded on Ni-NTA resin columns, washed and then eluted with a buffer containing 250mM imidazole (Figure 35). Because of the poor purity of GlyA-His6 elution fractions, thedouble tagged Strep-GlyA-His6 protein was prepared from the pET-52b-glyA plasmid. Thedouble tag allowed purification on Ni-NTA followed by a second step using Strep-Tactinresin. The Strep-tag did not bind to the resin in the second purification and better puritywas not achieved (data not shown). Gel filtration chromatography, an approach to separateproteins according to their sizes, was also tried to get better purity. GlyA was not recoveredin the expected elution fractions, which might be a result of protein degradation (data notshown).
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Figure 35: SDS-PAGE gel showing the protein purification of GlyA-His6 (58.8 KDa)
from C. pneumoniae.Marker: Novex Sharp Pre-stained Protein Marker (Invitrogen)
4.2.2 Detection of racemase activity of chlamydial GlyAThe ability of the SHMT GlyA from C. pneumoniae to catalyze the interconversionbetween L-alanine and D-alanine was tested in vitro. GlyA was incubated with L- or D-alanine in presence of the co-factor pyridoxal phosphate. At the end of incubation time (4or 24 hours), the amount of produced or consumed D-alanine were analyzed using afluorescent coupled enzyme assay based on D-amino acid oxidase and horseradishperoxidase catalyzed reactions in the presence of the fluorescent substrate QuantaBlu.The chlamydial GlyA catalyzed the conversion from L-alanine to D-alanine after 24hours of incubation. Short incubation for 4 hours was not enough to detect the racemaseactivity in vitro, indicating weak catalytic activity of the chlamydial protein. GlyA from
C. pneumoniae did not require the addition of external pyridoxal phosphate, during the
Results 83racemization reaction. This might indicate that pyridoxal phosphate bound to the enzymeduring the purification process was enough or that chlamydial GlyA does not requirepyridoxal phosphate for its activity. The physicochemical properties of several SHMTs fromeukaryotic origin were investigated before and the SHMT from mung bean showedpyridoxal phosphate-independence [146] (Figure 36 A-B).The enzyme bound pyridoxal phosphate has an absorption maximum in the range of422-430 nm [99, 147, 148]. D-alanine was detected in this reaction using a fluorescentcoupled-enzyme assay, in which fluorescence at 425 nm was measured. Removal of theenzyme bound pyridoxal phosphate before detecting D-alanine may be important toincrease sensitivity of the assay.On the other hand, conversion of D-alanine to L-alanine could not be detected afterboth 4 and 24 hours of incubation (Figure 36 C-D). This might indicate a weaker affinitytowards D-alanine than L-alanine or low sensitivity of the applied test system to detectconsumption of D-alanine in presence of high background of the D-amino acid. It wasstated before that GlyA from E. coli binds L-alanine more tightly than D-alanine [98].Establishing an assay to detect the release of L-alanine rather than consumption of D-alanine might help to increase the sensitivity to detect the racemase activity of D-alanine toL-alanine.
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Figure 36: Racemase activity of chlamydial GlyAGlyA was incubated with L- or D-alanine with or without the addition of pyridoxal phosphate (PLP).The D-alanine produced (A+B) or remaining (C+D) after 4 hours (A+C) or 24 hours (B+D) ofincubation was detected with the activity of D-amino acid oxidase enzyme in presence of QuantaBlufluorescent substrate.To control for the background racemase activity of the high number of co-purifiedproteins, MurC-His6 over-produced in the E. coli Bl21 strain and purified on Ni-NTA wasused as a negative control with all reaction conditions and did not show any racemizationactivity. Because of different patterns of contaminating proteins in the elution fractions ofthe purified MurC-His6 and GlyA-His6, more controls are still required. Detection ofracemase activity in harvested chlamydial RBs might be helpful to confirm the D-alaninebiosynthesis in chlamydiae ex vivo.
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4.3 FUNCTIONAL ANALYSIS OF CHLAMYDIAL PBPSThe sensitivity of chlamydiae to penicillin and other β-lactam antibiotics isattributed to the presence of three PBPs encoded in the chlamydial genome. Chlamydiaehave three PBPs homologous to PBP2, 3 and 6a from E. coli. PBP2 and PBP3 are essentialmono-functional transpeptidases in E. coli. On the other hand, the E coli PBP6a shows aweak in vitro carboxypeptidase activity. To get insights into the functionality of thechlamydial PBPs, cloning, over-production and purification of the three proteins areessential preparatory steps.
4.3.1 Cloning over-production and purification of chlamydial
PBPsCloning, over-production and purification of PBPs, even by other species, are ingeneral very challenging and difficult. It was supposed that secondary structures in thegenes may hinder the cloning, and toxicity of the gene product may inhibit good levels ofexpression. The presence of membrane anchors may affect the feasibility of proteinpurification. For those reasons, a strategy using different promoter systems, purificationtags and chaperones was applied. Chlamydial PBP2, PBP3 and PBP6a were clonedseparately in pASK-IBA3, pASK-IBA5 and pET-21b to build the constructs shown in Figure37, Figure 39 and Figure 41. Positive clones were selected by colony PCR and wereconfirmed by restriction endonuclease reactions (Figure 38, Figure 40 and Figure 42).Protein expression in pASK-IBA vectors is under the control of tetApromoter/operator region. In absence of the inducer, anhydrotetracycline, the promoter istightly repressed by constitutive expression of tet repressor gene encoded on the vector.Complete repression of the promoter was considered beneficial for the over-production ofproteins with expected toxicity like PBPs. A disadvantage of the tetA promoter is its lowstrength (only 25% the strength of the T7 one). On the other hand, protein expression inpET-21b vector is under the control of the strong T7 promoter with a leaky constitutiveexpression, which might show problems with cloning and expression of genes encodingproteins with expected toxicity.
Results 86While pASK-IBA3 and pASK-IBA5 introduced a Strep-tag to the recombinant proteinat its C-terminus and N-terminus respectively, pET-21b vector fused a His6-tag to the C-terminus of the recombinant protein.
Figure 37: Schematic presentation of the recombinant plasmids pASK-IBA3-PBP2 (A),
pASK-IBA5-PBP2 (B) and pET-21b-PBP2 (C)RS = restriction site
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Figure 38: Detection of positive clones from recombinant plasmids pASK-IBA3-PBP2
(A lane 3), pASK-IBA5-PBP2 (B lane 3) and pET-21b-PBP2 (C lane 3) using restriction
analysis and agarose gel electrophoresis.One mg of plasmid DNA was restricted for 1 hour with NdeI (A and B) or NdeI/NotI (C). DNAladder: 1 Kb DNA ladder (Fermentas)
Figure 39: Schematic presentation of the recombinant plasmids pASK-IBA3-PBP3 (A),
pASK-IBA5-PBP3 (B) and pET-21b-PBP3 (C)RS = restriction site
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Figure 40: Detection of positive clones from recombinant plasmids pASK-IBA3-PBP3
(A lane 3), pASK-IBA5-PBP3 (B lane 5) and pET-21b-PBP3 (C lane 3) using restriction
analysis and agarose gel electrophoresis.One mg of plasmid DNA was restricted for 1 hour with NdeI/EcoRI (A) or NdeI/XhoI (C). DNAladder: 1 Kb DNA ladder (Fermentas)
Figure 41: Schematic presentation of the recombinant plasmids pASK-IBA3-dacF (A),
pASK-IBA5-dacF (B) and pET-21b-dacF (C)RS = restriction site.
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Figure 42: Detection of positive clones from recombinant plasmids pASK-IBA3-dacF
(A lane 3), pASK-IBA5-dacF (B lane 3) and pET-21b-dacF (C lane 3) using restriction
analysis and agarose gel electrophoresis.One mg of plasmid DNA was restricted for 1 hour with XbaI (A and B) or NheI/XhoI (C). DNAladder: 1 Kb DNA ladder (Fermentas)
4.3.2 Over-production and purification of recombinant
chlamydial PBPsPurification of Strep-tagged PBPs from the pASK-IBA3 recombinant plasmids wasnot achieved and attributed to one or more of the following reasons: (i) inaccessibility ofthe Strep-tag at the C-terminus, (ii) very weak or no protein expression because of itsexpected toxicity and/or (iii) formation of inclusion bodies that hinder the recovery of theprotein in the soluble fraction during cleared lysate preparation. Moving the Strep-tag tothe N-terminus using the pASK-IBA5 recombinant vectors disproved the first optionconcerning the accessibility of the tag. To check the protein expression and solubility, thesoluble and insoluble fractions of the cleared lysates were tested by western blotting,followed by chemiluminescence detection of Strep-tagged proteins using Strep-Tactinhorseradish peroxidase conjugate. A very weak signal was detected in the insolublefraction in case of PBP3 cloned in pASK-IBA5 vector (data not shown). Despite the use ofdifferent detergents, PBP3 could not be solubilized and recovered from the insolublefraction.
Results 90The T7 promoter system was used to overcome the weak expression level achievedwith the pASK-IBA vectors. None of the three recombinant proteins showed sufficient over-expression from the pET-21b recombinant plasmids. This might be a result of the toxicityand/or misfolding of the PBPs.Over-production and purification of the three chlamydial PBPs were successfullyestablished exploiting T7 driven expression in combination with co-expression ofchaperones and fusion of C-terminal His-tags.To improve the expression of chlamydial PBPs, co-expression with pKJE7 (TaKaRa)chaperone plasmid encoding chaperones DnaK, DnaJ, and GrpE was used. Co-expression ofa target protein with chaperones has been shown to increase recovery of expressedproteins in the soluble fraction. The induction of the three PBPs was greatly improved inpresence of the chaperones but the proteins remained in the insoluble fraction of the celllysate. Using N-lauroylsarcosine (0.5 %), all His6-tagged PBPs could be solubilized andpurified using Ni-NTA resin (Figure 43 and Figure 44).
Figure 43: SDS-PAGE gel showing the protein purification of PBP2-His6 from
C. pneumoniaeMarker: Novex Sharp Pre-stained Protein Marker (Invitrogen)
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Figure 44: SDS-PAGE gel showing the protein purification of PBP3-His6 (A) and
PBP6a (B) from C. pneumoniae.Marker: Broad Range protein marker (NEB)The apparent molecular masses of the purified PBP3 (~66 KDa) and PBP6a (~43KDa) as determined by SDS-PAGE were different from the calculated ones (73.3 and 49.1KDa respectively). Discrepancies in the apparent molecular masses of chlamydial PBPsdetected in membrane preparations of the RBs by binding to labeled penicillin werereported before. While Barbour et al. [120] showed that the apparent molecular masses ofPBP2, PBP3 and PBP6a from C. trachomatis are 88, 61 and 36 KDa respectively, Stroy andChopra [121] stated that the apparent molecular masses of these proteins are 110, 73 and40 KDa respectively.
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4.3.3 In vitro tests for transpeptidase activity of chlamydial
PBP2 and PBP3A recent study showed that the division of chlamydial RBs ceases by the secondcycle of binary fission in the presence of penicillin [24]. Chlamydial PBPs might beresponsible for processing of lipid II in the periplasm. Due to their sequence similarity tothe transpeptidases PBP2 and PBP3 from E. coli, in vitro assays were first established todetect the functionality of the transpeptidase domain of the chlamydial proteins.
4.3.3.1 Using the natural substrates, lipid II and PG sacculiIn a recent study by Born et al. [106] the transpeptidase domain of a bi-functionalPBP1A from E. coli was not able to exhibit a transpeptidase activity in the absence of afunctional transglycosylase domain. Based on these results, mono-functionaltranspeptidases such as PBP2 and PBP3 from C. pneumoniae might not show in vitroactivity disconnected from transglycosylation. That is why, a mutant of the bi-functionalPBP2 from S. aureus (prepared by Anna Müller) with a functional transglycosylase domainand dysfunctional transpeptidase domain was included in an assay to detect thetranspeptidase activity of the chlamydial PBP2 and PBP3. The principle of the reaction isbased on analyzing the ability to attach lipid II to PG sacculi in vitro. PBPs were incubatedwith PG sacculi from E. coli W3110 or B. subtilis for 10 minutes before mixing with lipid IIin presence or absence of 0.05% Triton X-100. The reaction was incubated at 30°C for 2hours and centrifuged to remove the PG sacculi. The lipid content of the supernatant wasextracted and analyzed on TLC to show whether lipid II was utilized as a substrate fortransglycosylation and transpeptidation reactions.Under the applied conditions, the PBP2 and PBP3 from C. pneumoniae did notexhibit a transpeptidase activity in absence or presence of the transglycosylase domain ofPBP2 from S. aureus. Being from Gram-positive origin, the transglycosylase domain of thestaphylococcal PBP2 mutant was not active when tested alone under the reactionconditions (pH 7.5) (Figure 45).
Results 93In a very recent study, Banzhaf et al. [149] showed that upon mixing the bi-functional E. coli PBP1A mutant, with a dysfunctional transpeptidase, and the mono-functional transpeptidase PBP2 from E. coli, no transpeptidase activity was detected
in vitro. On the other hand, when the mono-functional PBP2 and bi-functional PBP1A wild-type proteins were combined in the assay, a significant increase in the overalltranspeptidase activity was detected in comparison to reactions mediated with PBP1Aalone. This increase was confirmed to be due to the transpeptidase activity of the mono-functional PBP2. These results indicate that establishing an assay using a bi-functional
E. coli PBP, with functional transglycosylase and transpeptidase activities, together with thechlamydial PBP2 and PBP3 might be beneficial to detect putative transpeptidase activities
in vitro.
Figure 45: Investigation of transpeptidase activity of PBP2 and PBP3 from
C. pneumoniaePBPs (10-20 µg each) were mixed with PG sacculi on ice, then lipid II (2 nmol) was added. After 1hour of incubation at 30 °C, the PG sacculi were removed by centrifugation. Supernatants wereanalyzed for changes in lipid II content using TLC. Sa PBP2-TP* is PBP2 from S. aureus withdysfunctional transpeptidase domain. Cp: C. pneumoniae, Sa: S. aureus
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4.3.3.2 Using the artificial thioester S2d substrateAnother approach to detect the transpeptidase activity of the chlamydial PBP2 andPBP3 was detecting the ability of these proteins to hydrolyze the thioester N-benzoyl-D-alanylmercaptoacetic acid (S2d), an analogue of the bacterial cell wall stem peptide [135-137]. In this assay, the chlamydial PBP2 or PBP3 was incubated at 37˚C with S2d inpresence of 4,4’-dithiopyridine, which has been shown to couple with the S2d hydrolysisproduct and to increase the sensitivity of the assay [135]. The increase of the absorbance at325 nm was used as a measure for the transpeptidase activity.First trials did not show differences between the samples containing chlamydialproteins and a negative control in which the PBPs were replaced by Tris buffer (Figure 46).The detected increase in the absorbance at 325 nm is attributed to the auto-hydrolysis ofthe thioester.Under applied conditions, chlamydial PBP2 and PBP3 did not exhibit transpeptidaseactivity in both test systems using natural and artificial substrates. More conditions shouldbe tested to verify these results in both test systems.
Figure 46: Investigation of transpeptidase activity of chlamydial PBP2 or PBP3 using
the thioester S2d as a substrate.PBP2 or PBP3 from C. pneumoniae was incubated with 1 mM S2d and 0.8 mM 4,4’-dithiopyridine ina buffer system containing 10 mM phosphate buffer pH 7 with or without 10% DMSO. Absorbanceat 325 nm was measured every 10 minutes for 1 hour. A negative control using Tris buffer insteadof PBPs was performed as well.
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4.3.4 In vitro tests for carboxypeptidase activity of chlamydial
PBP6aDue to sequence similarity to the carboxypeptidase PBP6a from E. coli, test systemswere first established to detect the functionality of the carboxypeptidase domain of thechlamydial protein. To examine whether the chlamydial PBP6a has a carboxypeptidaseactivity, the enzyme was tested for the release of the terminal D-alanine from the naturalpentapeptide substrate lipid II or the artificial tripeptide substrate Nα,Nε-diacetyl-L-lys-D-ala-D-ala. Incubation of lipid II with a carboxypeptidase leads to the hydrolysis of theterminal D-alanine and the production of lipid II variant with tetrapeptide stem, which isexpected to migrate differently from lipid II containing pentapeptide stem on TLC. For theartificial substrate, the released D-alanine was detected using the fluorescent-coupledenzyme assay described in section 4.2.2In both test systems, no carboxypeptidase activity was detected for PBP6a from
C. pneumoniae (Figure 47). This might be due to very weak activity of the chlamydialprotein that has been shown for several E. coli carboxypeptidases as well. In a recent studyusing soluble variants E. coli PBP6, the protein showed very weak activity in vitro (oneseventh the activity of PBP5, the major carboxypeptidase in E. coli) using the artificialsubstrate Nα,Nε-diacetyl-L-lys-D-ala-D-ala. On the other hand, the E. coli protein showed nocarboxypeptidase activity with the pentapeptide natural substrate [150]. The PBP6b,another carboxypeptidase in E. coli encoded by dacD gene showed very weak activity in an
in vivo study as well [151]. Based on these results, very weak enzymatic activity is highlyexpected for the chlamydial PBP6a.
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Figure 47: Investigation of carboxypeptidase activity of PBP6a from C. pneumoniae
using the artificial substrate Nα,Nε-diacetyl-L-lys-D-ala-D-ala (A) and the natural
pentapeptide substrate lipid II (B)(A) D-alanine released was detected with the activity of D-amino acid oxidase in the presence offluorescent substrate QuantaBlu. For the positive control a carboxypeptidase form E. coli was used.(B) After incubation with PBP6a, no change in the lipid II migration was detected.
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4.3.5 In vivo interaction between chlamydial PBP3 and AmiAIn E. coli, the amidase AmiA cleaves the amide bond between MurNAc and the firstamino acid in the peptide side chain L-alanine [152]. It is thought that chlamydial AmiA andPBP3 may play an important role in the processing of lipid II and the recycling of the lipidcarrier C55-P. Bacterial two hybrid analyses (done by bachelor student Karolina Schulz)suggested that chlamydial PBP3 interacts with AmiA (Figure 48). A relatively low β-galactosidase activity was expected from assays that take place in the periplasm.
Figure 48: Bacterial two hybrid studies on in vivo interactions between chlamydial
PBP3 and AmiA (K. Schulz)Protein interactions were quantitatively determined by measuring β-galactosidase activities ofthree individually selected replicate cotransformants. The β-galactosidase activities are expressedin Miller Units (change in A420/min/ml/OD600) as mean values (± standard deviation). Unpaired t-test revealed statistical significance in comparison to empty vector negative control (T25×T18), **:p-value≤0.01
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5 DISCUSSIONCompared to free living bacteria like E. coli, prokaryotic intracellular pathogenshave a remarkabley reduced genome size. C. trachomatis [25], Mycoplasma pneumonaie[153], Rekettsia conorii [154] and Rekettsia prowazekii [154, 155] have genome sizesranging between 0.9-1.2 Mb, while E. coli [156] has a genome size of about 4.6 Mb. Thereduced genome is suggested to be a result of hindered uptake of foreign DNA in theseorganisms because of their intracellular environment [157]. Other reasons includedifferential loss of genes that lost their functions or genome decay with increasedadaptation to host cells [158]. For example, many genes coding for proteins involved inamino acid biosynthesis and some regulatory proteins have been discarded from thegenomes of R. prowazekii and M. genitalium [159, 160]. Genome of C. trachomatis lacks thegene encoding thymidylate synthase required for the synthesis of deoxythymidinemonophosphate [25] supporting the evidence that the latter is acquired from the host cell[161, 162].During adaptation to the isotonic intracellular environment, chlamydiae did notneed to keep a functional cell wall to guard against osmotic rupture and a cell wall hasnever been reliably detected. Surprisingly, chlamydiae retained the biosynthetic pathwayof cell wall precursor lipid II [2, 25]. Additionally, chlamydiae lack the essential organizer ofcell division FtsZ but harbor the cytoskeletal protein MreB [25]. These findings opened adiscussion on how chlamydiae can organize its cell division in absence of the cell divisiondriving FtsZ and the role of the shape-maintaining cytoskeletal protein MreB despite oftheir spherical shape.Cell division and cell wall biosynthesis in prokaryotes are driven by partiallyoverlapping multiprotein machineries. Absence of tight coordination between the activitiesof these machineries may disrupt cell integrity. Recently, it was proposed that conservationof lipid II biosynthesis in cell wall-lacking endobacteria may reflect the intimate molecularlinkage of cell wall biosynthesis and cell division and thus a vital role of the bactoprenolbound precursor in cell division [95].
Discussion 99In this study, it was investigated whether MreB plays a role in spatially organizinglipid II biosynthesis reactions in chlamydiae. The functionality of MreB was investigated.Results from in vitro light scattering and sedimentation assays showed that chlamydialMreB polymerized. The in vitro results were supported by BACTH analysis, in which MreBshowed a significant self-interaction in vivo. Polymerization of chlamydial MreB wasfavored in slightly acidic buffers (pH 6.5), in presence of Mg+2 and in presence of MurF. Thepolymerization was strongly inhibited at K+ concentration as low as 20 mM, which wasshown recently for MreB from B. subtilis [140]. In vivo studies proved that B. subtilis MreBcan polymerize under physiological conditions (e.g. [163, 164]) with K+ concentrations ofabout 300 mM [165]. Modulation and control of MreB polymerization in vivo may beaffected by the interplay of enhancing mechanisms (protein interaction) and inhibitorymechanisms (salt susceptibility).MreB from C. pneumoniae, B. subtilis and T. maritima show more that 54% aminoacid identities. Despite these high sequence similarities, the three proteins differ in theirdependence on nucleotides for polymerization and their susceptibility towards A22. Likeall actin homologs, chlamydial MreB is a functional ATPase, nevertheless, in contrast toMreB from T. maritima [130], the proteins from C. pneumoniae and B. subtilis [140]polymerize independently from ATP.A22 is frequently used in vivo studies on the bacterial MreB cytoskeleton. E. coliloses its rod shape upon treatment with A22 [141]. This compound was identified in vitroas a competitive inhibitor of ATP binding to MreB from T. maritima and A22-bound MreBhas a greatly reduced affinity for polymerization [143]. The minimal inhibitoryconcentration (MIC) of A22 towards B. subtilis is extremely high (100 mg/L) comparable toMreB-lacking spherical bacteria S. aureus (>100 mg/L) and in contrast to susceptibleorganisms like E. coli and Salmonella typhimurium with MIC of 3.13 mg/L [66]. Inaccordance with ATP-independent polymerization, A22 did not inhibit polymerization ofwild-type and C345A mutant MreB in vitro. Moreover, A22 did not inhibit ATP hydrolysisby chlamydial MreB indicating that the compound cannot bind the nucleotide-bindingpocket of MreB from C. pneumoniae.
Discussion 100A22 affects bacterial growth not only by acting on MreB but also on (an)otheressential unknown target(s). This has been shown in several recent reports on (i) E. colimutant lacking MreB, (ii) an A22 resistant Anabaena mutant strain retaining a wild-type
mreB gene, and (iii) rod-shaped bacteria containing (C. crescentus) or not containing(Sinorhizobium meliloti, Agrobacterium tumefaciens) MreB [166, 167]. Further studiesdealing with the in vivo effect of A22 on chlamydiae, bacteria with reduced genome size andA22-resistant MreB, might be of importance to identify these unknown targets.In this project, it was shown that chlamydial MreB interacts with MurF, MraY andMurG, three key components of lipid II biosynthesis. MreB and MurG have been shown tolocalize at the division site in E. coli and C. crescentus [70, 168, 169]. Moreover, in a veryrecent study [170], BACTH system analyses showed that chlamydial MreB interacts withthe multifunctional cell division protein FtsK.From the last discussed results and based on the hypothesis that lipid IIconservation in cell wall-less bacteria is required for functional cell division [95], MreBcould be involved in maintaining coordinated cell division via tethering the biosynthesis oflipid II to the chlamydial septum (Figure 50).This hypothesis regarding chlamydial MreB is supported by a recent study on L-forms of B. subtilis [171]. L-forms are atypical bacteria that are cell wall-deficient and ableto grow as spheroplasts [172]. They are osmotically fragile and seem to lack the usualcoordinated binary fission process of division of typical bacteria [173]. The stable L-formsgenerated in the study by Leaver et al. did not require FtsZ for cell division [171]. It waspostulated a FtsZ independent extrusion-resolution mechanism in which a cytoskeletalsystem (built up by B. subtilis actin homologs MreB, Mb1 or MreBH) or an activechromosome segregation system might provide force generation. Moreover, L-formmutants lacking D-alanine racemase, responsible for D-alanine synthesis from L-alanine,can grow in the absence of D-alanine supplements, and electron microscopy did not detectany residual cell wall outside the boundary of the cytoplasm or at the division site. Thesefindings are in good agreement with the hypothesis that monomeric cell-wall precursorlipid II is required for cell division in Chlamydiaceae as bacteria of these family lack a cellwall and lack also D-alanine racemase [95].
Discussion 101During longitudinal growth of rod-shaped bacterial like E. coli, the membranespanning proteins, MreC and MreD, play an important role in connecting the cytoplasmicMreB-organized-precursor-biosynthesis machinery to the PBP2-catalyzed incorporation oflipid II in the periplasm (Figure 6A) [65, 70]. While MreC and MreD are encoded in thegenomes of elongated bacteria in one operon together with MreB [65], both proteins aremissing in chlamydiae. For spherical bacteria, shape maintaining functions and spacialorganizing of PBP2 reactions are dispensable. Therefore, chlamydiae may have notretained MreC and MreD.Under stress conditions, chlamydiae can enter a reversible non-infectious but viablestate known as persistence. Treatment of chlamydiae-infected cells with the cell wallbiosynthesis inhibitor penicillin can induce such a state of persistence, in which celldivision is arrested by the second cycle. RBs continue to grow and synthesize chromosomaland plasmid DNA forming enlarged and aberrant RBs known as penicillin bodies (Figure 3).Upon removal of penicillin, a normal developmental cycle is recovered [24]. Binding ofpenicillin to chlamydial PBPs may interrupt processing of lipid II and cell division might bearrested due to depletion of the bactoprenol carrier. Sensitivity of chlamydiae to treatmentwith cell wall synthesis inhibitors like penicillin, D-cycloserine and bacitracin in absence ofclear-cut biochemical evidence for the presence of PG cell wall is a paradox know aschlamydial anomaly.Besides the conservation of lipid II biosynthesis pathway in the chlamydial genome,other findings confirm the functional biosynthesis of cell wall precursors in chlamydiae.The nucleotide oligomerization domain (Nod) proteins, interacellular receptorsrecognizing different fragments of PG [85, 87-89], are indispensible for sensing andgenerating immune response to intracellular infections with C. pneumoniae [83], andNod1/Nod2 knockout mice showed delayed innate immune response and bacterialclearance [82].Chlamydial genomes encode 3 PBPs, which are the target for the action of penicillin[120]. D-cycloserine inhibits the activity of both alanine racemase (Alr) and D-alanyl-D-alanine ligase (Ddl) [174]. No clear evidence until now confirmed that chlamydial genomesencode any homologs of Alr but Ddl is encoded as a fusion protein with MurC [25, 175,
Discussion 102176]. Sensitivity of chlamydiae to bacitracin shows that recycling of the lipid carrierbactoprenol is essential for chlamydiae and its developmental cycle. Bacitracin bindsbactoprenol pyrophosphate (C55-PP) inhibiting its dephosphorylation and recycling.Interestingly, chlamydiae are resistant to fosfomycin [93], a bacterial cell wall synthesisinhibitor that binds irreversibly to and inhibits the activity of MurA due to its structuralsimilarity to phosphoenolpyruvate (PEP) [177]. Sequence analysis of MurA from
C. trachomatis showed a cysteine to aspartate change in a key residue within the active siteof the enzyme [93]. The same amino acid change was previously described in MurA mutantfrom E. coli to induce resistance to fosfomycin [178]. Additionally, the same natural aminoacid change was described in Mycobacterium tuberculosis. Changing this amino acid backfrom aspartate to cysteine renders MurA from M. tuberculosis sensitive to fosfomycin [179].Although the chlamydial anomaly is known since the early 90s, the molecular basisof this phenomenon is not elucidated yet. Until today, the activity of cytosolic chlamydialproteins MurA [93], MurC/Ddl [90, 94], MurE [91] and MurF [92], transmembrane proteinMraY [95] and the membrane associated protein MurG [95], involved in lipid IIbiosynthetic pathway have been proven. Moreover, an alternative pathway was detectedfor the biosynthesis of the third amino acid in the peptide side chain, m-DAP [96]. Despiteall these findings supporting the idea that chlamydiae synthesize lipid II, the exactstructure of lipid II-peptide side chain in chlamydiae is not yet confirmed.MurC, the enzyme responsible for the addition of the first amino acid in the stempeptide, from C. trachomatis uses L-alanine, L-serine and glycine as a substrate in vitro withcomparable efficiency [90]. Indeed, this lack of specificity in vitro makes the amino acid inthe first position of the stem peptide not clear and depends mainly on the availability of theamino acids in the intracellular pool [90].Chlamydiae do not encode glutamate racemase (MurI), the enzyme needed for thesynthesize of D-glutamate from its L-isomer [2]. Additionally, the functionality of thechlamydial MurD, the ligase enzyme responsible for the addition of the second amino acid(D-glutamic acid) to the peptide side chain, is not proven until now. Despite the absence ofMurI and doubts about the MurD activity, MurE from C. trachomatis can recognize MurNAc-L-alanine-D-glutamate in vitro [91].
Discussion 103For the biosynthesis of the third amino acid in the peptide stem, m-DAP, anaminotransferase pathway was described in chlamydiae using the activity of CT390 andDapF proteins [96]. The addition of the third amino acid is catalyzed by the activity of MurEligase. Patin et al. showed that chlamydial MurE ligase is functional and can complementthe activity in E. colimutant with impaired MurE [91]. In vitro, chlamydial MurE recognizednot only m-DAP as a substrate, but meso-lanthionine and D-lysine as well but with muchweaker activity [91].In the last cytoplasmic step of lipid II biosynthesis, MurF ligase adds the dipeptideD-ala-D-ala to the peptide stem completing the pentapeptide side chain. In a recent study,chlamydial MurF could complement the growth of E. coli murF temperature-sensitive lysismutant at its restrictive temperature [92]. The chlamydial enzyme prefers m-DAP at thethird position of the peptide stem to L-lysine, the latter is found mainly in Gram-positivebacteria [92]. Moreover, the enzyme can catalyze the addition of the dipeptide D-ala-D-serand D-ala-gly as efficient as D-ala-D-ala [92]. The capability of chlamydiae to synthesize thedipeptide D-ala-D-ala via the activity of the Ddl domain of the MurC-Ddl fusion protein wasconfirmed in vitro [94].Although the results on functionality of chlamydial MurF and Ddl domain of thefusion protein MurC-Ddl and sensitivity of chlamydiae to D-cycloserine and penicillinsuggest that D-alanine is present in chlamydial lipid II, the source of this D-amino acid inchlamydiae is still unknown. Chlamydiae lack the alanine racemase Alr, which isresponsible for D-alanine synthesize in other bacteria. Moreover, genes encoding homologsto D-amino acid transaminases, enzymes that can synthesize D-amino acids, could not bedetected in chlamydial genomes [2]. Additionally, no evidence supports the hypothesis thatD-alanine is supplied to chlamydiae from the mammalian hosts as they do not containsufficient concentrations of D-amino acids [180]. alr knock-out mutants of Listeria
monocytogenes could not survive within mammalian cells without exogenous supplementof D-alanine [181]. Together, these findings support the hypothesis that chlamydiaesynthesize D-alanine on their own.One aim of this project was to show how chlamydiae could synthesize D-alanine.Chlamydial genome encodes a serine hydroxymethyl transferase (SHMT) GlyA. The glyA
Discussion 104gene was initially transferred from an actinobacteria to a common ancestor of the familyChlamydiales by lateral gene transfer [101]. The hypothesis that chlamydial GlyA mightserve as a source for D-alanine required for lipid II synthesis in such bacteria is supportedby the results of a recent study on an alr/dadX-deficient E. coli strain. This strain exhibiteda D-alanine auxotrophic phenotype. Transcriptome analysis of D-alanine prototrophicrevertants showed a significant upregulation of genes involved in methionine synthesisincluding GlyA [100]In this study, the preliminary results on the in vitro racemase activity of thechlamydial SHMT GlyA show that the protein may provide a way to synthesize D-alanine bythese bacteria. Chlamydial GlyA could catalyze the conversion of L-alanine to D-alanine,which was not true for the negative controls without GlyA or with MurC. These findingsprovide another indication that lipid II in chlamydiae contains the terminal dipeptide D-ala-D-ala. Lipid II and nascent chains of PG containing D-ala-D-ala are the substrate for thereactions catalyzed by PBPs.A complete cycle of lipid II biosynthesis and processing, including translocationacross the membrane and recycling of the bactoprenol carrier is needed to maintain acoordinated function of the divisome machinery. Until now, the fate of lipid II in chlamydiaeis unclear. While these obligate intracellular pathogens encode the flippase FtsW, anintegral membrane protein, which translocates lipid II to the outer side of the cellmembrane [25, 49], their genomes lack other enzymes essential for the processing of lipidII in the periplasm. Bacteria of the family Chlamydiaceae lack transglycosylases andendopeptidases that are needed to link the sugar units of lipid II to form glycan chains andto cleave peptide bridges between cross-linked glycan strains, respectively [25].Additionally, they do not encode pyrophosphorylases, which catalyze in E. coli the recyclingof the lipid carrier C55-P by dephosphorylating its pyrophosphate form C55-PP [52-54].Moreover, chlamydial genomes encode two mono-functional transpeptidases (PBP2 andPBP3 (FtsI)) [25], which cross link the glycan chains via peptide bridges in free-livingbacteria. They encode a DD-carboxypeptidase (PBP6a) [25] that catalyzes the removal ofthe terminal D-alanine from the peptide side chain. They possess as well a gene coding an
Discussion 105amidase (AmiA) [25] that cleaves peptide side chains from glycan chains during celldivision in extracellular bacteria (Figure 49) [182].
Figure 49: Schematic presentation of amidase (Ami), endopeptidase (EPase) and DD-
carboxypeptidase activities on peptidoglycan (modified from [182]).Chlamydiae are susceptible to treatment with penicillin and other β-lactamantibiotics as they harbor three PBPs homologous to PBP2, PBP3 and PBP6a from E. coli[27, 78, 120]. Due to expected difficulty in PBPs cloning and over-expression, the threegenes were cloned in three different vectors with different promoter systems, tags and tag-positions. Cloning in pASK-IBA vectors with the tightly repressed tetA promoter showedhigher rates of positive clones in comparison to pET-21b vector with constitutive T7promoter. The predicted secondary structures in the PBPs genes may hinder theattachment to the restricted pET-21b vectors during ligation step. The weak expression ofPBPs, with their expected cytotoxicity, induced by the constitutive T7 promoter may resultin dramatic selection against the E. coli that harbor the recombinant vector. Additionally,good levels of protein over-production that allow successful protein purification were notachieved using the three recombinant vectors under different conditions for induction andpurification. Improper folding of foreign or cytotoxic proteins is a common problem ofover-expression in E. coli that leads to protein degradation by proteases and/or inclusionbody formation. With the help of co-expression of a chaperone plasmid pKJE7 that encodesthree chaperone protein (DnaK, DnaJ and GrpE), the three chlamydial PBPs were
Discussion 106successfully over-produced and purified. Because of the predicted transmembranedomains, the expressed proteins were solubilized with help of sodium lauroylsarcosine(0.5%). An alternative technique was to clone truncated proteins that lack the predictedtransmembrane domain, which may impair the protein folding and activity. Therefore, thecloning of full-versions of the three PBPs was preferred.The genome of E. coli encodes 12 PBPs, of which only PBP2, PBP3 with one of the bi-functional proteins PBP1a or PBP1b are enough to maintain the wild-type phenotype of thebacteria [113]. In the genome of C. trachomatis, the gene encoding PBP3 is located in anoperon upstream of murE and amiA and downstream of mraW and the gene for thehypothetical protein CT272. In all Gram-negative bacterial murE and mraW are part of thedivision cell wall (dcw) cluster [183, 184].mraW is an essential gene for cell division that isuniversally distributed in all bacteria and encodes a cytoplasmic protein withmethyltransferase activity [185]. The genomic environment of the PBP3 encoding genestrongly supports its role in cell wall division in chlamydiae.In the diploma thesis by Anna Klöckner, the in vitro activity of AmiA from
C. pneumoniae to hydrolyze lipid II was detected using a dye release assay. The chlamydialprotein recognized both lipid I and lipid II as a substrate. An in vivo interaction betweenchlamydial AmiA and PBP3 was detected using BACTH system analyses.In this project, in vitro assays were established to test the transpeptidase activity ofchlamydial PBP2 and PBP3 using natural and artificial substrates. It was not possible todemonstrate transpeptidase activity by PBP2 and PBP3 from C. pneumoniae under testedconditions. Optimizations for both assays are still required to test the functionality of bothproteins. Utilization of a bi-functional PBP from Gram-negative origin like E. coli, instead ofthe staphylococcal protein, may allow the transglycosylation reaction to be performed atthe same reaction conditions. The PG sacculi involved in the assays were from E. coli and
B. subtilis origins, which offer a substrate with length and cross-linking degree that differsfrom the natural substrate expected for cell wall-less bacteria. PG sacculi from otherbacterial origins may present a better substrate for the chlamydial proteins. Detection oflipid II attached to PG sacculi using a radioactive labeled lipid II variant [106, 149] mayincrease the sensitivity of the assay to detect the activity of chlamydial PBP2 and PBP3.
Discussion 107In a very recent study on PBP2 and PBP3 from C. trachomatis [170],immunofluorescent microscpic analyses of chlamydiae treated with the PBP-specificantibiotics, mecillinam or piperacillin, showed clear morphological changes indicatingsensitivity of chlamydiae to both compounds [170]. While mecillinam is a selectiveinhibitor of the transpeptidase activity of PBP2 from E. coli [186-189] inducing loss of itsrod shape [190], piperacillin blocks the activity of PBP3 from E. coli selectively [118, 188,191, 192] resulting in filamentous E. coli [191]. Additionally, BACTH system analysesrevealed interactions between chlamydial PBP2, PBP3, self-interaction for dimerization ofPBP3 and association of PBP2 and PBP3 with the multifunctional cell division protein FtsK[170]. These findings confirm the functionality of the chlamydial HMM-PBPs and their rolein coordinating cell division and recycling of lipid II.The established assays to test the carboxypeptidase activity of the chlamydial PBP6ashowed no activity under tested conditions using both natural and artificial substrates. Thegenome of E. coli encodes several DD-carboxypeptidases, PBP4, PBP5, PBP6a and PBP6b ofwhich PBP5 is the most abundant and most powerful carboxypeptidase [33, 193]. Previousstudies revealed a very weak activity for PBP4, PBP6a and PBP6b [150, 151, 194]. Despitethe close sequence similarity between PBP5 and PBP6a (65% identical), the latter wasunable to substitute for PBP5 function in vivo [195]. With the exception of PBP5, which hasa clear role in maintaining cell diameter and typical morphology in E. coli, othercarboxypeptidases seems to be dispensable and the conservation of these non-essentialenzymes in E. coli is still questionable [193]. Two hypotheses were postulated for thefunction of PBP6a in E. coli. First: PBP6a may have a carboxypeptidase activity similar toPBP5 but with much lower efficiency, however, many observations are not consistent withthis hypothesis [193]. Second: PBP6a of E. coli may be involved in the production of lipid IIvariants with tripeptide side chain [196], which is thought to be the substrate for PBP3during septation [118, 197]. Over-expression of PBP6a can restore cell division infilamentous E. coli mutants due to extremely reduced levels of PBP3 expression [196]. Theexact mechanism for tripeptide generation by PBP6a is poorly understood [193].Additional studies are still required to test whether chlamydial PBP6a follows the first orsecond hypothesis.
Discussion 108Based on the previously discussed results on chlamydial proteins, the followingmodel for the linkage between lipid II biosynthesis and cell division in chlamydiae could beproposed (Figure 50). MreB interacts with MurF, MraY and MurG and serves as a scaffolddirecting lipid II biosynthesis to the septum. The synthesized precursor is processed by arudimentary cell wall biosynthesis-cell division machinery. Lipid II is translocated acrossthe membrane by the activity of the flippase FtsW. Subsequently, PBP2, PBP3 and AmiA areinvolved in catalyzing reactions that result in unknown products and the release of thebactoprenol carrier. During such a process, a rudimentary (glycan-less [78]) by product, inwhich the peptide side chains are cross-linked by peptide bonds, might result. Recycling ofC55-P lipid carrier is unclear in the absence of pyrophosphorylases (YeiU, YbjG, PgpB andUppP) that have been described so far to dephosphrylate C55-PP in E. coli.[54]It should be noted that 28% of the predicted proteins from the chlamydial genomesequencing showed no sequence similarity to any of known proteins [25], therefore, noclear function could be assigned for these proteins. Analysis of the functionality of theseunknown proteins may offer better elucidation of the chlamydial anomaly.
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Figure 50: Proposed model for co-ordination of lipid II biosynthesis and cell division
in chlamydiaeA complete cycle of lipid II biosynthesis and processing, including translocation to the outside andrecycling of the bactoprenol carrier needs to be maintained for coordinated function of the celldivision machinery (which may consist of FtsW, FtsI, FtsH, FtsK and FtsY). The actin homolog MreBfunctionally organizes MurF, MraY and MurG and directs lipid II biosynthesis to the septum. Thesynthesized precursor is translocated to the outside where the release of the bactoprenol carrier iscatalyzed through the activity of FtsI, PBP2 and AmiA.Question marks and dashed arrows indicate steps of the proposed pathway that remain to beelucidated (GlcNAc: N-acetylglucosamine; MurNAc: N-acetylmuramic acid)Orchestration of lipid II biosynthesis and processing as well as cell division may beachieved by formation of multi-enzyme complexes. Additional studies on the interaction ofMreB with proteins involved in these fundamental processes will be helpful for a betterunderstanding into the role of MreB in functionally organizing lipid II biosynthesis at theseptum and as such in maintaining functional division machinery. Deeper insight in co-ordination of lipid II biosynthesis and cell division will contribute to elucidate theinscrutable chlamydial anomaly at a molecular level. In addition, it will provide a basis forthe design of new antibacterial drugs to combat diseases caused by these majorintracellular pathogens.
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6 SUMMARY AND CONCLUDINGREMARKSChlamydiae are Gram-negative, obligate intracellular pathogens. Because of theisotonic intracellular niche of the host, a functional cell wall is dispensable in theseendobacteria. Surprisingly, a nearly complete pathway for the biosynthesis of cell wallprecursor lipid II is conserved in chlamydiae. Moreover, the organism is susceptible topenicillin and other antibiotics that inhibit cell wall biosynthesis. This paradox, which isknown as chlamydial anomaly, raises the question about the essential role of cell wallbuilding block lipid II in maintaining bacterial growth and replication.Cell wall biosynthesis and cell division in prokaryotes are driven by tightlycoordinated, partially overlapped machineries. Therefore, it was hypothesized that lipid II,which is an essential part of both processes, is required to maintain a functional divisomein chlamydiae.The bacterial actin homolog MreB, which is found exclusively in non-sphericallyshaped bacteria, is considered to organize the incorporation of cell wall precursors into theside-wall, whereas the tubulin homolog FtsZ, which is ubiquitously distributed in almost allbacteria, is known to tether incorporation of cell wall building blocks at the developingseptum. Unexpectedly, chlamydial genomes lack the essential central organizer of celldivision ftsZ, but harbor despite of its spherical shape the rod-shape determiningmreB.In this project, it was investigated how chlamydiae can divide in absence of FtsZ. Itwas demonstrated that cytoskeletal protein MreB might compensate for FtsZ formaintaining a functional divisome machinery in chlamydiae. It was shown that chlamydialMreB polymerizes in vitro and that polymerization is not inhibited by the blocking agentA22. As observed for MreB from B. subtilis, chlamydial MreB does not require ATP forpolymerization but is capable of ATP hydrolysis in phosphate release assays. Co-pelletingand bacterial two-hybrid experiments indicate that MreB from C. pneumoniae interactswith MurF, MraY and MurG, three key components in lipid II biosynthesis. In addition,MreB polymerization is improved in the presence of MurF. These findings suggest thatMreB is involved in tethering biosynthesis of lipid II and as such may be necessary formaintaining functional divisome machinery in Chlamydiaceae.
Summary and Concluding Remarks 111While chlamydial genomes lack the alr gene encoding for alanine racemase that isresponsible for D-alanine synthesis in other bacteria, several findings suggest that D-alanine should be part of chlamydial lipid II. Preliminary results on the racemizationactivity of the chlamydial GlyA show that the protein may provide D-alanine in chlamydiae.The sensitivity of chlamydiae to penicillin and other β-lactam antibiotics isattributed to the presence of three PBPs encoded in the chlamydial genome. Chlamydiaehave three PBPs homologous to PBP2, 3 and 6a from E. coli. PBP2 and PBP3 are essentialmono-functional transpeptidases in E. coli. On the other hand, the E. coli PBP6a shows aweak in vitro carboxypeptidase activity. To get insights into the functionality of thechlamydial PBPs, the three proteins were cloned, over-produced and purified successfully.Further optimizations for the established assays are still required to get clear insights intothe functionality of these proteins in Chlamydiaceae.
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